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 May, 2015 
Colorectal cancer (CRC) is the third most common cancer worldwide and the 
fourth most common cause of death. These are staggering statistics for a disease that can 
essentially be cured if caught early and the pathology is favorable to therapeutic 
intervention. There is currently a drastic decrease in five year survival as the cancer stage 
increases from locally confined disease to metastatic disease. These statistics suggest that 
although some strides have been made with colon cancer screening and early 
intervention, there is still much room for improvement in both screening and treatment of 
CRC.  
One of the pathways that have been linked to CRC is the mammalian target of 
rapamycin (mTOR) pathway. Recently this has been the subject of intense study 
particularly with a view to better targeted drug therapy for colorectal cancer. Much is 
known about this pathway; however, multiple regulatory elements have yet to be 
elucidated.  MicroRNAs (miRNAs) have been shown to influence some aspects of the 
mTOR pathway in other cancers, however their role in the mTOR pathway in CRC has 
vi 
 
yet to be fully explored. The microRNA-99 (miR-99) family of miRNAs has recently 
been implicated in regulation of mTOR signaling in other diseases.  
Studies were conducted using normal colon epithelial and CRC cell lines provided the 
following key findings: 
1. Transfection of miRNA-99a mimic into CCD-841 (normal epithelium) and 
CRC cell lines, HT-29 (Dukes C), HCT-116 (Dukes D), results in a decrease 
in the amount of phosphorylated mTOR protein in all 3 cell. 
2. miRNA-99a transfection also affected expression of downstream protein 
products, with a decrease phosphorylated S6K1 in HT-29 and CCD-841, 
while this same transfection showed an increase in this phosphorylated protein 
in cell line HCT-116. The opposite was observed for protein 4EBP1 after 
transfection, which showed an increase in phosphorylated 4EBP1 in cell lines 
HT-29 and CCD-841, but a decrease in phosphorylated protein the HCT-116 
cell line. 
3. Transfection of miRNA-99a mimic resulted in decreased motility and 
invasion in cell lines HT-29 and HCT-116 as compared to cell lines 
transfected with the negative control. Transfection with the miRNA-99a 
antagomir resulted in increased motility in both CRC cells lines but minimal 
changes or decrease in invasion.  
The effects of miRNA-99a on mTOR protein, S6K1 and 4EBP1 were elucidated 
by this project providing further evidence as to the importance of mTOR inhibition for 
vii 
 
possible regulation of CRC metastasis. This supports new avenues of study to further 
understand CRC metastasis as well as possible targets for therapeutic intervention.
viii 
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COLORECTAL CANCER: A SIGNIFICANT CLINICAL PROBLEM 
A. EPIDEMIOLOGY 
Colorectal cancer is a major cause of morbidity and mortality. As of 2011, it was 
the third most common cancer worldwide and the 4
th
 most common cause of death.
1
 In 
the United States, in 2013, it was the third most common cancer among men and women 
accounting for 96,830 new cases of colon cancer and 40,000 new cases of rectal cancer 
and in turn 50,310 colorectal cancer deaths annually.
1
 These statistics suggest that 
although some strides have been made with colon cancer screening and intervention, 




Figure 1: 5 Year Survival and Distribution of Colorectal Cancer Based on 



























Early screening appears to have led to a delayed but meaningful reduction in 
disease mortality. Although this is a significant advance for clinicians and their patients, 
the side effects and preoperative preparation that are involved in colon and rectal cancer 




Current recommendations for colon cancer screening for patients that are not a 
“high risk” for colon cancer begins at the age of 50 and continues until the age of 75.
3
 
There are currently 3 accepted screening tests; each has its benefits and downsides, each 
occurring at different intervals. The first screening test is the high-sensitivity fecal occult 
blood test, which is recommended once yearly. The upside of this is the lack of invasive 
nature and no need to undergo bowel preparation; the downside of this test is it is not 
specific for colon cancer and detects any blood that is in one’s gastrointestinal tract. The 
second screening test is flexible sigmoidoscopy. The recommended interval of this test is 
every five years with the addition of fecal occult blood test done every three years. The 
advantage of this test is the clear visibility of the lower part of the colon and rectum, but 
the downside is its invasiveness and patient discomfort. In addition, the clinician is 
unable to visualize the entire colon. Colonoscopy is the currently accepted “best 
screening” method and most complete screening test. It is recommended every 10 years 
for patients who are not at high risk. The benefits of colonoscopy are complete 
visualization of the colon and potential intervention when polyps are detected. Downsides 
of colonoscopy include the laxative bowel preparation for this procedure, the risk of 
bowel perforation and operator skill set, both with respect to completeness and safety.  To 
5 
 
state the obvious, colonoscopy does not come without risk. The unpleasant nature of this 
bowel preparation leads to imperfect compliance and reduces the effectiveness of the 
colonoscopy itself.  
D. TREATMENT OPTIONS 
Current therapy focuses on endoscopic and surgical intervention.
3
 The additions 
of chemotherapy and radiation therapy come into play when regional or distant metastasis 
are a factor. Due to the advances over the last several decades in endoscopic surveillance, 
more cases of colon cancer are detected at an early stage prior to metastasis.
3
  
Early stages of colon cancer are treated and may be cured with polyp removal. 
This is why screening colonoscopies are so important- because when a polyp is 
recognized and removed prior to the polyp converting to an invasive mass, it can be 
essentially “cured” at the time of endoscopy. If the polyp progresses to an invasive, 
cancer but has not metastasized to the lymph nodes, this also can be treated with surgical, 
often laparoscopic, resection (Figure 2). Colon cancers can be treated with segmental 





Figure 2. Colorectal Cancer Progression from Benign Polyp to Invasive Tumor 
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E. CASE SCENARIOS ILLUSTRATING LIMITATIONS OF CURRENT 
SCREENING GUIDELINES 
With a variety of screening tests whose goal is early intervention, there are still 
clinical scenarios where large bowel tumors are missed for several reasons. This can be 




A 48 year old woman presents to her primary care physician with a 
several week history of blood seen in her stool. She undergoes a focused 
history and physical. She does not have a family history of any cancer or 
disease processes. She denies weight loss but does state that her bowel 
movements have been somewhat irregular as of late. Upon physical exam, 
her doctor does notice some external hemorrhoids with some blood on 
them. Since she does not have a family history of colon cancer and she is 2 
years away from recommended “normal screening” for colon cancer, the 
doctor attributes the blood seen in the stool to the current hemorrhoids and 
provides treatment for this.  
The same patient returns 2 years later, now with weight loss and 
lack of energy. She has not had any other blood noticed in her stool since 
her visit 2 years prior.  Now that she is 50, and due to the nature of weight 
loss and weakness, her physician now recommends a screening 
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colonoscopy, during which a large partially obstructing cancer is seen in 
her transverse colon. In her evaluation prior to resection, a liver lesion is 
noticed. She is optimized for her operation and upon elective operation is 
found to have a bulky transverse colon cancer which is resected with a 
primary anastomosis; the lesion in the right lobe of her liver is biopsied 
and the mass is found to be adenocarcinoma consistent with colon cancer. 
She now requires systemic chemotherapy and/or a major liver resection 
for this metastasis. Her likelihood of surviving 5 years is less than 40%.  
 Case 2 
A 60 year old woman has a several day history of blood in her 
stool. She presents to her primary care physician who performs a history 
and physical examination. Her most recent colonoscopy was 10 years ago 
and no polyps or masses were observed at the time. Since her last 
colonoscopy was 10 years ago and she is “due” for a screening exam, her 
personal physician schedules her for this procedure. During the 
colonoscopy, she is noted to have a locally advanced cancer in her 
sigmoid colon. She is subsequently scheduled for further evaluation and 
operative resection of the cancer and primary anastomosis. She recovers 
from her operation and the pathology reports show adenocarcinoma that 
has penetrated the bowel wall but is free of metastasis in the 16 lymph 
nodes removed intraoperatively. At 6 month follow up, she remains well 
and her primary relatives are notified by the patient of these events, since 
all relative now have a “positive” family history.   
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 Both of the above scenarios would benefit from a more accurate screening 
examination to determine if an individual needs colonoscopy sooner than the 
recommended interval screening. In Case 1, the individual is “two years too young” for 
the recommended screening age, yet if a simple blood based test could tell the clinician of 
a possible polyp or cancer, then intervention could presumably be undertaken prior to 
development of a distant metastasis. Intervention prior to metastasis is key, as the 5 year 
recurrence rate for colorectal cancer drastically increases once distant metastasis is 
present.  
F. CURRENTLY AVAILABLE PLASMA-BASED BIOMARKERS FOR 
COLORECTAL CANCER 
Carcinoembryonic antigen (CEA) assay is the most popular assay for clinical 
monitoring. It has been used for post-operative surveillance and for monitoring response 
to therapy. CEA, however, lacks sufficient sensitivity and specificity for screening or for 
detecting CRC recurrence.
4
 It also has been used as a prognostic marker.  CEA is 
normally elevated during the fetal development period but beyond that, it is not normally 
found in the blood. CEA levels may increase with distant metastasis but this assay does 
not have high specificity or sensitivity in regards to detection of distant metastases. In 
addition, CEA can be elevated in many other types of cancer, as well as falsely elevated 
in smokers.  
Carbohydrate antigen 19-9 (CA 19-9) has been used as a prognostic tumor marker, but it 
is less sensitive than CEA for CRC.
5
 Methylated septin 9 has been reported to have good 
sensitivity and specificity for CRC but does not have sufficient ability to detect colorectal 
adenomas.
6
 Markers in development include CSA (colon cancer specific antigen)-1, 2 
10 
 
and 3, colon-cancer-secreted-protein (CCSP)-2,
7, 8
 galectin-3-ligand and haptoglobin-
related-glycoprotein. 
Unfortunately, no accurate, broadly applicable test currently exists for colorectal 
adenomas that could identify candidates for intervention (colonoscopic removal) in order 
to prevent CRC or to diagnose CRC at an earlier stage (Table 2 a&b). This has been a 
focus of work in the Price Institute since 1995.
11 
 
Table 2. 5 year Survival Rates of Colon and Rectal Cancer  
 A. Colon Cancer by Stage  
5 Year Survival Rate  
Stage Survival Rate (%) 
I 92 
II A 87 
II B 63 
III A 89 
III B 69 
III C 53 
IV 11 
 
B. Rectal Cancer by Stage  
5 Year Survival Rate  
Stage Survival Rate (%) 
I 87 
II A 80 
II B 49 
III A 84 
III B 71 
III C 58 
IV 12 
 
*National Cancer Institute's SEER database, looking at people diagnosed with colon and 




PRELIMINARY DATA : MIRNA AS BIOMARKERS FOR COLORECTAL CANCER 
A. MIRNA OVERVIEW 
miRNAs are short noncoding RNA molecules that range from approximately 19-
23 nucleotides in length. They bind to complementary sequences on target messenger 
RNAs (mRNA). The affinity of binding can influence the effect of the miRNA on 
mRNA. miRNAs can cause translational repression, target sequence degradation and or 
gene silencing to name a few of their functions (Figure 3). miRNAs are a promising area 
to research because of their inherent stability intra- and extra-cellularly. Furthermore, 
they are known to be involved in numerous regulatory processes in the human body and 















B.  TISSUE AND PLASMA MIRNA IN CRC, INITIAL STUDIES 
Kanaan evaluated miRNA in both CRC tissue and normal mucosa. Levels of 380 
miRNAs were determined using microfluidic array technology (Applied BioSystems) in a 
“training” set of 30 CRC patients from whom cancer and nearby normal tissue were 
collected. The 4 most dysregulated miRNAs (P < 0.05, False Discovery Rate (FDR): 
10%) were then validated in a second blinded “test” set of 16 CRC patients from whom 
cancer and nearby normal tissue had also been collected. Nineteen of 380 miRNAs were 
dysregulated in CRC tissue in the tissue “training” set (P < 0.05, FDR: 10%). The 2 most 
upregulated (miR-31; miR-135b) and most down-regulated (miR-1; miR-133a) miRNAs 
identified CRC in our “test” set with 100% sensitivity and 80% specificity. MiR-31 was 
also more upregulated in stages III and IV compared with stages I and II (P<0.05).
11
 The 
most dysregulated tissue miRNAs were then validated in an independent new plasma test 
set consisting of 20 CRC patients with 20 age- and race-matched subjects without CRC. 
In the “plasma test” group, miR-21 differentiated CRC patients from controls with 90% 
specificity and sensitivity. Although these early results were promising, miR-21 has been 
described in other cancers. Thus, there is a need to develop a more specific plasma 
miRNA panel for CRC.  
C. PLASMA MIRNA TO DETECT PREMALIGNANT LESIONS OF THE 
COLON (ADENOMAS) 
We studied colorectal polyps or colorectal advanced adenomas (CAA) with the 
highest likelihood of malignant transformation over time. Advanced adenomas are 
defined as adenomas >0.75 cm, with a villous component or high-grade dysplasia and 
15 
 
represent a continuum from benign adenoma to invasive CRC. We screened 380 plasma 
miRNAs using microfluidic array technology (Applied BioSystems) in a screening cohort 
of 12 controls, 9 patients with CAA, and 20 patients with stage III & IV CRC. A panel of 
the most dysregulated miRNAs (P <0.05, FDR 5%) was then validated in a blinded 
cohort of 26 controls, 16 patients with CAA, and 45 patients with CRC. After testing the 
15 most dysregulated microRNAs in the validation group, a combined panel of miR-532-
3p, miR-331, miR-195, miR-17, miR-142-3p, miR-15b, miR-532 and miR-652 identified 
CAA accurately. This 8-miRNA panel demonstrated an AUC of 0.868 [95% CI 0.76-
0.98] in the plasma “validation” set, indicating good discriminative power.  Additionally, 
in the validation set, miR-139-3p and miR-431 were significantly dysregulated 
differentiating controls from all CRC stages (AUC = 0.829 [95% CI: 0.73–0.93]) (Fig. 5). 
Receiver-operating-characteristic (ROC) curves of miRNA panels for CAA versus all 
CRC showed an AUC of 0.856 (95% CI: 0.75–0.97). miRNAs specific for CAA and 
CRC were explored and identified.  Sensitivity and specificity values are based on the 
generated ROC curves for each miRNA panel.
12
 
D. DIFFICULTIES WITH ASSAY REPRODUCIBILITY 
miRNA expression profiles have been shown to be unique to both the source 
material (i.e. plasma, tissue, etc.) and the disease process being investigated. miRNA 




This has led to a rapid proliferation of miRNA research. Unfortunately, many 
studies have been conducted without attention to standardization of methods or 
reproducibility of results, particularly with respect to studies of plasma miRNA. In many 
16 
 
reports, it is difficult to deduce the actual methods used for analysis.  This has led to the 
use of different extraction protocols, and various methods of quantification and statistical 
analysis, which, in turn, are a source of variability (Table 3).  In part, due to this lack of 
standardization, many different miRNAs have been reported to be associated with a given 
disease process 
15
. There is ongoing controversy over the optimal analytic methods for 






Table 3. Multiple sources of variability in microRNA data and literature search 12, 19-93. 












 Preservation Method 
-     Formalin fixed-paraffin embedded 
-     Snap Frozen  
 Collection Method 
- Laser caption microdissection 
- Macrodissection (includes stroma) 
Plasma 
 Collection method (e.g. EDTA tube) 
 Method to isolate plasma 
Other body fluids (urine, 
cerebrospinal fluid, etc.) 













  Immediate (within 24 h) 
 Delayed  
Method of RNA extraction*†
 
 Guanidinium thiocyanate-phenol chloroform based ( e.g. 
Trizol LS,  LifeTechnologies) 
 Glass fiber filter-based methods (e.g. miRVANA, 
Ambion) 
 Phenol/guanidine-based with and silica membrane based 
purification (e.g. miRNeasy, Qiagen) 
Type of miRNA*
  Total  
























s miRNA characterization 
 Cyanine dye-based RT qPCR (SYBR® Green) detection 
 Fluorogenic 5’ nuclease-based RT qPCR detection 
 Deep sequencing 
Quantification* 
 Absolute (addition of exogenous miRNA e.g. C. elegans  
miRNA) 
 Relative (use of an internal reference e.g. RNU48, 
RNU44, RNU47, RNU6, miR-16) 
Cycle threshold bar*† 
 Fixed threshold 
 Variable threshold 
Statistical analysis*† 
 Paired t-Test 
 Wilcoxon Signed Rank test 
 Cycle Threshold ratios 
 Rank-based 
Reproducibility† 
 Intra-operator comparisons  
 Inter-operator comparisons 




Since the discovery of miRNAs, their detection in blood has received much attention 
due to the ease of access and ready availability of peripheral blood as compared to tissue 
15
. Initially, we performed a systematic review of publications focusing on plasma 
miRNA in order to ascertain what methods and reporting criteria were currently being 
utilized. We then we used a panel of 11 selected miRNA to study the effect of time to 
plasma extraction,  method of RNA extraction,  cycle threshold bar setting, intra-operator 
variability , inter-operator variability and selection of housekeeping gene on data 
obtained in plasma miRNA studies.
94, 95
 An in-depth description of our statistical analysis 
is found in the analysis section, however a full statistical model-based approach, such as 
analysis of variance or analysis of covariance (ANOVA or ANCOVA) was used to 
analyze the data.
94 
1. SYSTEMATIC REVIEW 
 In order to determine the consistency and current status of methods reporting of 
clinical studies of plasma miRNA, we retrieved original manuscripts published from July 
1, 2013, until June 30, 2014.  We utilized a single search engine (PubMed) without 
language restriction using the following search words:  plasma, microRNA, and human. 
We excluded review articles, case reports, or non-English language articles. Remaining 
articles were then obtained for review. These were then graded as to how many of the 
following criteria were clearly documented in the Materials and Methods sections: 1) 
time of plasma extraction, 2) method of RNA extraction, 3) type of miRNA used (total vs 
exosomal), 4) method of quantification (external vs internal reference), 5) cycle threshold 
bar setting, and 6) methods of statistical analysis (items denoted by * in Table 2).  
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 Of the 220 retrieved abstracts, 130 were excluded because they were reviews, 
case reports, or non-English language manuscripts. Sixteen publications were 
unobtainable through our library, leaving 74 manuscripts available for review. A 
PRISMA flow diagram is shown in Figure 4 and data shown in Table 4. 
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Table 4. Systematic review: 74 plasma miRNA publications July 1, 2013 - June 30, 2014. 
 
Methodologic Parameter Assessed 
Number of studies  
(% of total 74 manuscripts  
reviewed) 
Time of Plasma Extraction  
    ≤ 2h 44 (59.5) 
    >2h 8 (10.8) 
    Not Stated 22 (29.7) 
Method RNA Extraction+  
    Trizol 13 (17.6) 
    miRNeasy 25 (33.8) 
    mirVana 30 (40.5) 
    Not Stated/Other 8 (10.8) 
Type of miRNA used  
    Total miRNA 72 (97.3) 
    Exosomal miRNA 2 (2.7) 
Cycle Threshold Bar Setting  
    Fixed 2 (2.7) 
    Variable 1 (1.4) 
    Not Listed 71 (95.9) 
miRNA Quantification*  
    External reference 31 (41.9) 
    Internal reference 32 (43.2) 
    Not specified 12 (16.2) 
Statistical Analysis Described  74 (100) 
    t-test 30 (40.5) 
    Mann-Whitney 29 (39.2) 
    Receiver operating characteristic 
(ROC) curves 
24 (32.4) 
    Wilcoxon 16 (21.6) 
    ANOVA 12 (16.2) 
    Other 14 (18.9) 
 
  + Some manuscripts utilized more than one method of RNA extraction. 
  * Some manuscripts used both an internal and external reference. 
   Many manuscripts used multiple methods of statistical analysis. 
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Although nearly one-third of studies did not mention time to plasma, in the vast 
majority (nearly 58%), plasma extraction was completed ≤2h after phlebotomy. Most 
authors used either Trizol, miRNeasy, or mirVana protocols for RNA extraction, and 
nearly all publications used total miRNA rather than exosomal miRNA. Equal 
proportions of manuscripts used internal and external references (43% and 42%, 
respectively). The most commonly utilized internal reference miRNAs were miR-16 (12 
publications) and RNU-6 (7 publications). Seventy-one of the 74 reviewed publications 
did not describe the setting of the cycle threshold bar. All but 2 of the 74 (97%) papers 
stated at least some aspect of their statistical methods, with many using multiple, 
different testing methods as shown in Table 2. Among reviewed manuscripts, only 1 (1.4 
%) listed all 6 assessed criteria 27-102. 
 
2. MICRORNA SELECTION 
An eleven miRNA panel with RNU6 as an internal reference was used. These 
miRNAs were selected based upon unpublished data from our laboratory utilizing 380 
miRNA arrays (Applied Biosystems, Carlsbad, California) to determine miRNA 
expression in the plasma of 20 colorectal cancer  (CRC) patients, and 10 patients each 
with colorectal advanced adenoma (CAA)(adenomatous polyps> 0.6 cm in maximal 
diameter), breast cancer (BC), lung cancer (LC), pancreatic cancer (PC), and 10 controls.  
In order to determine sample size, the most important aspect is adjustment of the 
significance level (alpha). For screening studies, we use Jung’s procedure to adjust the 
alpha. Using the method of Jung to find about 5% of features to be significant at a false 
detection rate (FDR) of 5%, the adjusted alpha will be 0.0038. With any two groups, a 
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minimum of n1=10 and n2=10 using a two sample t test, we can detect at least 2.7 fold 
means (which we have observed in our preliminary data sets) using the common standard 
deviation at significance level of 0.0038 and power of 80%. 
With respect to choice of number of miRNA in our panel, it was our expectation 
that no more than 10% of miRNA would be differentially expressed between cases and 
controls after adjusting the p values for multiple comparisons. Of these, in turn, one 
would not expect more that 0.5 to 3% of miRNA to be able to accurately identify cases 
and controls. Ten miRNA and one reference (housekeeping gene) miRNA were, 
therefore, chosen (approximately 3%).  Statistical analysis using ANOVA identified 11 
significantly dysregulated miRNAs specific for colorectal neoplasia (Table 2). Multiple 
test control was based on controlling the false discovery rate (FDR) at 10%. A logistic 
regression model was established using the top up-regulated miRNAs and used for 
predicting the adenoma and control groups for the validation data. The sensitivity and 
specificity for this prediction were calculated. The receiver operator characteristic (ROC) 
curves with area under the curve (AUC) values were microRNA-rated using current 
versions of SAS 
96
  and R 
97-99
 (Figure 1a & b).  
 
3. PATIENT POPULATION  
The University of Louisville Institutional Review Board reviewed and approved 
this study. Written informed consent was obtained from all subjects who were treated at a 
single university-based colorectal surgery practice. The patient population consisted of 16 
patients with colorectal advanced adenomas, and 16 patients without colorectal neoplasia 
(controls). The patient groups were age-, race-, and gender-matched. Prior to patient 
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treatment, 6 mL of peripheral whole blood was obtained in EDTA tubes (Becton-
Dickinson, Franklin Lakes, NJ) via venipuncture from the adenoma group and from 
individuals in the “control” group at the time of routine screening colonoscopy. The latter 
group of individuals (n=16) had no colonic neoplasia or inflammatory bowel disease. 
Blood was stored at 4ºC until plasma isolation. Plasma was isolated within 24 h of 
venipuncture, unless noted otherwise (see section below “Time to Plasma Extraction”). 
Patient demographics are displayed in Table 3 and did not differ between patient groups.  
 
4. TIME TO PLASMA EXTRACTION 
 Five 6 mL aliquots of peripheral blood from 6 controls were obtained and stored 
at 4ºC until extraction. Plasma was extracted at different time points: immediately (within 
30 minutes after phlebotomy) and then at 12, 24, 48, and 72 h post-phlebotomy.  Whole 
blood was centrifuged at 600 relative centrifugal force (rcf) for 15 minutes in order to 
isolate the plasma, which was then stored at -80ºC for later use. Once plasma was 
isolated, it underwent downstream processing via the modified phenol/guanidine-based 
lysis and silica membrane-based extraction technique (miRNeasy, Qiagen, Venlo, 
Limburg). 
 Our proposed standard technique provided a comparison. When performing 
plasma extraction from whole blood at different time points, we found that 6 miRNAs 
showed no differences in ∆CT values. In contrast, 5 miRNAs expressed a statistically 
significant difference in ∆CT values between immediate plasma extraction and extraction 
≥ 24 h for 1 miRNA  (miR-122), between immediate extraction and extraction after ≥48 h 
for 2 miRNAs (miR 485-3p, miR-21), and for 2 miRNAs with extraction at 72 h (miR 
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523, miR 218) (Table 5,). Based upon these data using the representative miRNA we 
have analyzed, plasma extraction less than 12h after phlebotomy appears to provide 
equivalent results to immediate (within 30 minutes of phlebotomy) extraction.  
 
5. EFFECT OF REPEATED SAMPLE ACQUISITION 
 In order to determine whether there was a difference between samples when 
plasma miRNA were analyzed in samples drawn at different times from the same 
individual, 6 mL peripheral blood was drawn from each of 12 healthy subjects without 
any neoplasia or inflammatory condition at 6:30 AM and 12 hours later at 6:30 PM on the 
same day. Plasma was extracted within 30 minutes of phlebotomy, and stored at -80ºC 
for later use. Downstream processing was performed using the modified 
phenol/guanidine-based lysis and silica membrane-based extraction technique 
(miRNeasy, Qiagen, Venlo, Limburg) and methodology described below. 
 Repeated phlebotomy of the same individuals at 12-hour intervals showed no 
differences in miRNA expression values (Table 5).
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Table 5.  Effect of Repeated Sample Acquisition. Comparison of mean CT’s for 
various plasma miRNA from plasma samples drawn from the same 7 






   
miR-374 -0.4458 0.454 
   
miR-142-3p -0.4136 0.4322 
   
miR-523 -0.5518 0.3424 
   
miR-374-5p -0.2611 0.6425 
   
miR-376c -0.4312 0.5867 
   
miR-27a -0.3863 0.4776 
   
miR-520d-5p -0.3081 0.7506 
   
miR-122 -0.0856 0.9251 
   
miR-485-3p -0.2611 0.6392 
   
miR-21 -0.3976 0.5261 
   
miR-218 -1.332 0.1659 
   




6. METHOD OF RNA EXTRACTION 
Total RNA was extracted from 250 µL plasma samples using either the TRIzol® 
LS reagent protocol (Ambion, Austin, Texas), which was modified by addition of an 
extended overnight drying period, or by a modified miRNeasy (Qiagen, Venlo, Limburg) 
extraction technique with yeast carrier 
100, 101
.  When using the TRIzol® LS total RNA 
extraction technique, pre-amplification was necessary, as the majority of samples yielded 
quantities of total RNA < 500 ng. In our experience, this is the minimum amount needed 
for adequate expression and amplification in qPCR. The Applied Biosystems protocol for 
producing custom reverse transcription and pre-amplification pools with TaqMan® 
miRNA assays was followed. Total RNA purity was assessed using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, Middlesex, MA). 
The Qiagen miRNeasy extraction without pre-amplification resulted in a higher 
yield of RNA than Trizol LS extraction; therefore, pre-amplification was not necessary 
and could be omitted as a source of possible variation (Table 6). The average ∆CT was 
lower with miRNeasy, with fewer missing values than with Trizol purification and pre-
amplification. Qiagen miRNeasy extraction without pre-amplification resulted in only 1of 
704 (0.14%) miRNAs not expressing; however, utilizing the Trizol LS extraction with 
pre-amplification, 109 of 704 (15%) of miRNAs investigated were not expressed (Table 
7). A heat map showing miRNA expression for patient groups is shown in Figure 5. A 
Step-One Plus RT-PCR System (Life Technologies, Carlsbad, California), with default 
fast thermal cycling conditions, was used for RT-PCR. Individual Taqman probes (20x) 
were used during RT-PCR to bind to a complementary sequence in the target cDNA.  
These values were, in turn, normalized to the expression of the endogenous miRNA 
28 
 








Table 6. Total RNA concentration and purity for Trizol LS and Qiagen miRNeasy with RNA yeast carrier. 

































Table 7. Inter-operator variability with two different extraction methods. Differences in ΔΔCT between Qiagen miRNeasy with RNA 
carrier and no pre-amplification and Trizol LS with pre-amplification. 
 Trizol LS with Preamplification  















miR-374 1.69 (±1.32) 0 0.70 (±0.78) 0 0.0006 
miR-142-3p 1.69 (±1.83) 0 0.91 (±0.89) 0 0.0340 
miR-523 1.45 (±1.45) 0 1.38 (±1.02) 0 0.8240 
miR-374-5p 1.69 (±1.73) 5 1.27 (±1.06) 0 0.2461 
miR-376c 2.42 (±1.42) 22 0.76 (±0.91) 0 <0.0001 




31 1.20 (±1.01) 1 0.0405 
miR-122 1.82 (±1.86) 13 1.11 (±1.10) 0 0.0642 
miR-485-3p 1.45 (±1.45) 0 1.50 (±1.01) 0 0.8734 
miR-21 2.40 (±1.82) 0 1.36 (±1.00) 0 0.0062 
miR-218 1.77 (±1.79) 32 1.09 (±1.06) 0 0.0692 
Total 1.79 (±1.63) 109/704 = 15%
a 
 1.12 (±0.99) 1/704 =0.14%
a 
<0.0001 
Comparison of Total Number of miRNAs Not Expressed by the Two Methods 
a
  <0.0001 
 
* 
|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT]. 
Bold = statistically significant. a = chi-squared test comparing number of miRNA not expressed using Trizol LS with preamplification as compared to using 







Figure 5. Heat map showing expression of 11 miRNA in plasma of 16 patients with colorectal adenoma prior to treatment and 




7. SETTING OF CYCLE THRESHOLD 
In order to compare cycle threshold (CT) values across plates, both fixed and 
variable thresholds were utilized.  Since different miRNAs on the same plate may have 
different linear phases, a fixed threshold may not intersect across the linear phase. For 
this reason, the variable threshold is the default setting.  The relative quantitation (RQ) 
manager from Applied Biosystems may use a different threshold (variable) within the 
same plate if one selects the option “automatic CT”. Different thresholds will be chosen 
for different miRNAs according to the linear phases.  However, these CT values cannot 
be compared directly between different plates. The threshold needs to be considered in 
the analysis and adjustment of the CT values, if needed. In addition to this variable 
threshold setting, we examined the effect of fixed threshold settings of 0.01, 0.03, 0.05, 
or 0.5. CT values, threshold, and 40 cycles fluorescence intensities are miRNA-rated 
from RQ manager 1.2, Applied Biosystems.  
 Setting the cycle threshold bar at a fixed value of 0.03 was preferable to using the 
default “variable” threshold setting, provided that the number of missing values was less 
than 10%. Using the modified phenol/guanidine-based lysis and silica membrane-based 
extraction technique (mirNeasy), only 0.14% of values were missing. With this method 
of extraction, therefore, utilization of a fixed threshold of 0.03 yields reproducible results 
without the need for normalization required with the use of a variable threshold.  
 
8. INTRA-OPERATOR VARIABILITY 
 Assays for individual miRNA for each patient sample were run in duplicate to 
permit assessment of intra-operator variability (comparison of duplicate samples).  
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 There was no significant variability between duplicate samples performed by a 








Table 8. Intra-Operator Variability (Duplicates) for the Trizol LS RNA Extraction and Preamplicification Protocol 
† 
|ΔCT| = absolute value (mean cycle threshold value for duplicate 1 for the miRNA of interest – mean cycle threshold value for duplicate 2 for the 
miRNA of interest. 
Colorectal Advanced Adenoma (n=16) + Control (n=16) 
microRNAs 
Mean CT Value  
Duplicate A (±SD) 







miR-374 25.98 (±1.80) 26.00 (±1.93) 0.02 0.9518 
miR-142-3p 28.48 (±2.77) 28.74 (±3.05) 0.27 0.6177 
miR-523 20.48 (±2.08) 20.21 (±1.71) 0.27 0.4240 
miR-374-5p 29.47 (±3.53) 29.81 (±3.61) 0.34 0.6186 
miR-376c 32.27 (±2.63) 31.68 (±2.33) 0.58 0.3265 
miR-27a 28.62 (±2.25) 29.24 (±2.99) 0.62 0.2216 
miR-520d-
5p 35.61 (±1.90) 35.24 (±1.77) 0.36 
0.4806 
miR-122 28.88 (±2.40) 29.11 (±2.82) 0.23 0.6814 
miR-485-3p 29.32 (±3.06) 29.44 (±3.32) 0.12 0.8320 
miR-21 26.97 (±2.58) 26.96 (±2.81) 0.01 0.9833 




9. INTER-OPERATOR VARIABILITY 
In order to assess inter-operator variation following total RNA extraction, two 
experienced operators separately performed subsequent sample processing, including 
reverse transcription, preamplification (for samples extracted using TRIzol LS), and 
qPCR. Each operator used the same thermocycler (Mastercycler, Eppendorf, Hamburg, 
Germany) and Step-One Plus RT-PCR System, but at different times on different days. 
The cycle threshold (CT ) values were exported with the CT bar set at 0.03.  
Inter-operator variability was assessed using two different miRNA extraction 
techniques. Inter-operator variability using the Trizol LS purification and pre-
amplification showed one miRNA miR-21 to be significantly different between 
operators. In addition, a large number of samples were noted to have no miRNA 
expression for 6 of the 11 evaluated miRNA (Table 9). The large number of samples with 
no miRNA expression again highlighted the importance of selecting the best extraction 
technique, since this was not seen with the other method (see also data Table 7). Inter-
operator variability using the Qiagen miRNeasy technique yielded 2 miRNAs (miR-485-
3p and miR-21) with statistically significantly different ∆CT values (p-values comparing 
the ∆CT of the two different operators, 0.0191 and 0.0500, respectively) (Table 10). It 
was believed that these differences in miRNA expression data between operators were 
within the range of experimental error. Indeed, when these experiments were repeated, 
these differences were not observed (data not shown). In order to determine whether any 
inter-observer differences would have a significant impact upon observed group 
differences we utilized an ANOVA model to examine variations in both miR-21 and 
RNU6. The group effect remained significant, even when there was an effect of inter-
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operator variability.  The coefficient of variation for RNU6 was 9.1398, and 8.1211 for 
miR-21. In addition, we determined the mean and standard deviation of 64 measurements 
of miR-21 performed in plasma samples of patients with adenoma (mean  26.3 ± 1.8 , 
median 25.9) as well as 64 measurements of miR-21 performed in plasma samples of 







Table 9. Differences in ΔCT between operators with Trizol LS RNA extraction and pre-amplification (inter-operator variability). 
 Colorectal Advanced Adenoma (n=16) + Control (n=16) 
Unpaired t-test  - Cycle Threshold = 0.03 





















miR-374 -1.95 (±2.53) 0 -1.53 (±2.39) 0 0.4974 1.69 (±1.32) 
miR-142-3p 0.84 (±1.99) 0 1.23 (±3.06) 0 0.5478 1.69 (±1.83) 
miR-523 -7.01 (±3.11) 0 -7.78 (±2.17) 0 0.2551 1.45 (±1.45) 
miR-374-5p 2.02 (±2.59) 2 2.83 (±2.85) 3 0.2577 1.69 (±1.73) 
miR-376c 5.83 (±2.21) 11 5.48 (±2.71) 11 0.6490 2.42 (±1.42) 
miR-27a 1.25 (±1.46) 1 1.50 (±1.77) 5 0.5580 1.29 (±1.23) 
miR-520d-
5p 
8.57 (±3.39) 14 7.00 (±2.73) 17 0.1587 
2.05 (±2.03) 
miR-122 2.41 (±4.23) 5 2.21 (±3.98) 8 0.8632 1.82 (±1.86) 
miR-485-3p 1.48 (±2.35) 0 1.34 (±2.50) 0 0.8182 1.45 (±1.45) 
miR-21 -1.83 (±2.60) 0 0.05 (±2.01) 0 0.0019 2.40 (±1.82) 







ΔCT = miRNA of interest cycle threshold value - U6 cycle threshold value.  
* 
|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT]. 
¥ = p value of mean ΔCT operator 1 vs operator 2. 







Table 10. Differences in ΔCT between operators with Qiagen miRNeasy with RNA Carrier and No Pre-amplification (Inter-
Operator Variability). 
 Colorectal Advanced Adenoma  (n=16) + Control (n=16) 
Unpaired t-test - Cycle Threshold = 0.03 





















miR-374 -1.80 (±1.75) 0 -1.69 (±1.99) 0 0.8151 0.70 (±0.78) 
miR-142-3p -7.16 (±1.57) 0 -6.60 (±1.81) 0 0.1910 0.91 (±0.89) 
miR-523 -3.21 (±2.82) 0 -2.12 (±2.92) 0 0.1339 1.38 (±1.02) 
miR-374-5p -3.27 (±1.94) 0 -2.33 (±1.87) 0 0.0529 1.27 (±1.06) 
miR-376c -0.04 (±1.74) 0 0.05 (±1.98) 0 0.8475 0.76 (±0.91) 
miR-27a -6.12 (±1.56) 0 -5.52 (±1.79) 0 0.1579 0.98 (±1.03) 
miR-520d-
5p 
5.54 (±2.54) 0 6.27 (±2.91) 1 0.2925 1.20 (±1.01) 
miR-122 -2.69 (±2.96) 0 -2.05 (±3.58) 0 0.4387 1.11 (±1.10) 
miR-485-3p -2.60 (±2.02) 0 -1.31 (±2.26) 0 0.0191 1.50 (±1.01) 
miR-21 -7.59 (±1.75) 0 -6.69 (±1.85) 0 0.0500 1.36 (±1.00) 




 1.12 (±0.99) 
† 
ΔCT = miRNA of interest cycle threshold value - U6 cycle threshold value.  
* 
|ΔΔCT|= Absolute Value [Operator 1 ΔCT – Operator 2 ΔCT]. 




10. SELECTION OF HOUSEKEEPING GENE (HKG) 
We determined expression of the following housekeeping genes (HKGs): Let-7a, 
Let-7d, Let-7g, miR-16, RNU6, RNU48, miR-191, miR-223, miR-484, and miR-520d-
5p. The cycle threshold (CT) was fixed at 0.03 for all samples. Once RT-PCR was 
performed for all samples, for each potential HKG, the mean CT and standard deviation 
was calculated for all sample groups, allowing for comparison among HKGs.
95
  
Following identification of the HKGs with uniform expression in all samples, and 
the narrowest standard deviation, we then used these HKGs alone or in combination as 
reference to determine their utility in comparing differences in miRNA expression 
between groups. Only miRNA which were expressed in ≥ 50% of subjects in each groups 
were analyzed.   
The number of samples in which these HKGs were expressed by patient groups is 
shown in Table 11. Let-7a, Let-7d, Let-7g, and RNU48 were only expressed in 26%, 7%, 
10%, and 8% of these samples, respectively. Only miRNAs with uniform expression in 







Table 11. Percentage of Housekeeping Gene (HGK) Samples Expressed within Each Group Investigated.  
 




















Let-7a 17 (85) 9 (82) 9 (90) 6 (60) 7 (70) 6 (50) 
Let-7d 19 (95) 10 (91) 10 (100) 7 (70) 10 (100) 12 (100) 
Let-7g 19 (95) 9 (82) 10 (100) 8 (80) 9 (90) 12 (100) 
RNU48 19 (95) 11 (100) 10 (100) 8 (80) 7 (70) 12 (100) 
miR-16 20 (100) 11 (100) 10 (100) 10 (100) 10 (100) 12 (100) 
mir-191-5p 20 (100) 11 (100) 10 (100) 10 (100) 10 (100) 12 (100) 
miR-223 20 (100) 11 (100) 10 (100) 10 (100) 10 (100) 12 (100) 
miR-484 20 (100) 11 (100) 10 (100) 10 (100) 10 (100) 12 (100) 
miR-520d-5p 20 (100) 11 (100) 10 (100) 10 (100) 10 (100) 12 (100) 




RNU6, miR-520d-5p, miR-16, miR-191, miR-223, and miR-484 were expressed 
in all samples. The mean CT and standard deviation for each of these remaining 6 
potential HKGs that were expressed in all samples are listed in Table 1. Figure 1 is an 
example of PCR output showing CT values of HKG U6 and miR-520d-5p.  RNU6, a 
commonly used HKG, was consistently expressed in all samples with a narrow standard 














* Data for RNU6 and miR520d-5p shown in shaded areas showed the narrowest standard deviation, with least variability between groups 
 Mean CT (+/- Standard Deviation) 
 RNU6* miR-16 miR-191 miR-223 miR-484 miR-520d-5p* 
Colorectal Cancer (n=20) 22.4 +/- 3.8  19.4 +/- 4.7 18.4 +/- 4.5 15.0 +/- 4.2 15.6 +/- 2.8 29.5 +/- 0.8 
Breast Cancer (n=10) 25.8 +/- 3.2 20.8 +/- 4.4 19.3 +/- 4.5 16.1 +/- 4.4 17.4 +/- 3.7 29.7 +/- 1.3 
Lung Cancer (n=10)  26.8 +/- 2.4 22.6 +/- 4.6 22.2 +/- 4.6 19.3 +/- 4.7 19.7 +/- 4.3 29.0 +/- 0.6 
Pancreatic Cancer (n=10) 27.3 +/- 2.2 25.2 +/- 2.1 21.3 +/- 4.7 19.8 +/- 3.2 17.8 +/- 3.1 30.4 +/- 0.8 
Colorectal Adenoma (n=11) 22.6 +/- 2.5 20.2 +/- 3.7 18.0 +/- 3.0 14.7 +/- 3.0 15.0 +/- 1.6 30.7 +/- 0.9 
Comparison (n=12) 22.0 +/- 2.2 21.2 +/- 1.8 20.1 +/- 2.7 17.5 +/- 2.7 17.2 +/- 1.6 30.5 +/- 1.0 
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In addition, our data indicated that a gene that has not been previously reported as 
an HKG (miR-520d-5p) had a remarkably stable expression over a variety of samples. Of 
all the HKGs we investigated, miR-520d-5p exhibited the narrowest range of expression 
(29.0-30.7) and the smallest standard deviation among samples as well as being 
expressed in all samples. Although we could find no reports describing use of miR-520d-
5p as an HKG, due to the reliable expression and narrow standard deviation, we suggest 
that it could be used reliably in plasma miRNA research.  
miRNA expression data using both HKG’s (RNU6 and miR-520d-5p) with the 
highest expression and narrowest standard deviation are shown in table 13. Overall use of 
RNU6 seems generally to be superior to using either miR520d-5p alone or the average of 
RNU6 and miR520d-5p; however because of greater variability within the same sample 
with RNU6, we would recommend using a combination of RNU6 and miR520d-5p.  
RNU6 has a higher expression than miR520d-5p. HKG with different expression than the 
miRNA of interest is recommended. Sample size does appear to play a role. For example 
in our comparison of controls vs all other groups, or in the comparison of CRC vs CRAd 
our sample sizes are small and/or unequal (unbalanced). In this scenario results are less 
clear, than where sample sizes are more equal and where results are more consistent 

































present in all 






in >80 of 
samples in 
both groups 
Control vs All Others*        
   RNU6 173 147 164 156 156 26 102 
   520d-5p 173 0 0 0 5 26 0 
     RNU6 & miR520d-
5p 
173 63 117 26 82 27 9 
(CRC & Crad) vs 
(BC,LC,PC) 
       
   RNU6 219 107 138 114 82 27 58 
   520d-5p 176 110 141 120 80 27 82 
   RNU6 & miR520d-
5p 
176 40 45 28 29 27 19 
CRC vs Crad        
   RNU6 219 2 2 2 8 43 1 
   520d-5p 219 1 1 1 17 43 0 
   RNU6 & miR520d-
5p 
219 3 1 1 11 43 0 
 






    
11. DISCUSSION  
With the growing field of miRNA research and the potential use of miRNAs as 
biomarkers for cancer and other human diseases, the lack of standardization and 
reproducibility among studies is becoming more apparent. Such variations in 
methodology can lead to large variability in results reported from one research group to 
another. Six different sources of variation in experimental technique were examined with 
respect to their effect on miRNA expression data: 1) time of plasma extraction, 2) method 
of RNA extraction, 3) cycle threshold setting, 4) intra-operator variability 5) inter-
operator variability and 6) selection of housekeeping gene. Our brief literature review of 
a 1-year time frame, was not meant to be an exhaustive review, but rather to provide a 
“snap-shot” of current practices of performing experiments and analyzing data. Our 
literature review has shown, that many publications focusing on plasma miRNA do not 
carefully describe their experimental methods, that there is wide variation in performing 
such studies and analyzing resulting data. 
There has been discussion as to whether plasma or serum is better for study of 
circulating miRNA. While some report comparable data others report differences 
between the two sources 
108-110
. We chose to focus on plasma, due to the concerns that 
miRNAs might be released from blood cells into the serum during the coagulation 
process as suggested by Wang et al 
109
. 
Our data regarding the timing of plasma extraction suggest that plasma needs to 
be isolated rapidly, within hours after phlebotomy. With blood samples that were stored 
at 4˚C, even with a modest sample size, we observed statistically significant different 
∆CTs for select miRNA beginning as early as plasma extraction at 24 h. This is in 
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agreement with prior reports linking hemolysis to altered miRNA expression 
111
. Due to 
the limited sample size and small number of miRNA investigated, we suggest that plasma 
be isolated within 12 h following phlebotomy in order to avoid falsely elevated or 
reduced miRNA expression levels.  
The three most widely used methods of total RNA extraction from plasma or 
serum are guanidinium thiocyanate-phenol chloroform-based methods (e.g., Trizol LS, 
Life Technologies, Carlsbad, CA), phenol with glass fiber filter-based (e.g. miRVANA, 
Ambion®, Life Technologies), and phenol/guanidine with silica membrane based 
purification (e.g. miRNeasy, Qiagen, Venlo, The Netherlands). Moret et al. 
101
 compared 
all three methods and found that a modified phenol/guanidine lysis with silica membrane-
based RNA extraction method yielded enhanced quantity, purity, and performance on 
assays. Although we did not assess the glass-fiber filter-based method here, our data 
agree with those of Moret et al. 
101
 and suggest that the Qiagen miRNeasy with yeast 
carrier isolation method yields a very reproducible result. The high concentration of 353 
+/- 85 ng/µL total RNA obtained with this technique as compared to Trizol LS, which 
resulted in concentration of 19 +/- 12 ng/µL, allows for pre-amplification to be omitted 
prior to qPCR, omitting yet another source of data variability. In using this technique, we 
were able to reduce the number of “missing” samples (miRNA that did not express) from 
15% to 0.14%. 
Analysis of various fixed as well as of variable threshold settings indicated that a 
fixed Ct setting of 0.03 produced the most reproducible data provided that < 10% of data 
were missing. This has the significant advantage of not requiring the additional statistical 
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adjustment that is required when a variable threshold is utilized (Rai et al., unpublished 
data, 2014). 
 We demonstrated a lack of significant intra-operator variability.  In view of this, 
triplicates are not necessary, and if there are few missing values (<10%), one could even 
question the need to perform duplicates given the very low ∆∆CT. Inter-operator 
variation was also low. Using the phenol/guanidine-based lysis and silica membrane-
based purification technique resulted in a narrowing of ∆∆CT values between operators 
as compared to guanidinium thiocyanate-phenol chloroform purification. In fact, when 
these experiments were repeated, the differences in miRNA expression between operators 
for miR-21 and miR-485-3p were not seen, leading us to conclude that this was within 
the range of experimental error and not a significant issue.  
 When determining CT values and normalizing miRNA expression of samples of 
interest to an internal HKG, it is imperative that the HKG be reproducible and express at 
similar values across all samples. An ideal HKG should meet the following criteria: 1) 
Expressed in all samples, 2) Have medium-to-high levels of expression in the specimens 
analyzed and 3) Have consistent levels of expression with narrow standard deviation. 
When applying these three criteria to our data, Let-7a, Let-7d, Let-7g and RNU48 were 
eliminated since they were not expressed in all samples. Of the 6 remaining potential 
HKGs, two had a very narrow standard deviation as well as consistent expression: RNU6 
and miR-520d-5p. Based upon our data, due to the narrow standard deviation and less 
variability among groups, we propose that both RNU6 and miR520d-5p should be used 
as HKGs.  
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Based upon our studies, rapid plasma extraction is essential. A modified 
phenol/guanidine-based lysis and silica membrane-based purification RNA extraction is 
preferred due to the extremely low rate of missing values and high RNA yield, allowing 
the investigator to avoid using pre-amplification, another source of variability. If there is 
a low number of missing values (<10 %), a fixed threshold setting of 0.03 provides the 
most reliable, consistent data without the need for data normalization. With this setting, 
there is no significant intra-operator variability, i.e. replicates can be restricted to 
duplicates, rather than triplicates, resulting in cost and labor savings. RNU6 and miR-
520d-5p are the most reliable of the 10 studied HKGs for studies of plasma miRNA. The 
use of plasma miRNA as biomarkers of human disease is evolving and expanding. Data 
reproducibility is essential prior to clinical application. Standardization of analytic 
methods and reporting is necessary to permit accurate data comparison and validation.   
 
A. COLON CANCER CELL LINES USED TO DETECT MIRNA DIFFERENCES 
BETWEEN CANCERS OF DIFFERING GROWTH RATES AND 
METASTATIC CAPABILITY 
The Price Institute at The University of Louisville allows for a unique situation to study 
tissue and plasma samples on patients that are followed clinically by the lead investigator. 
This gives a large range of pathology, but has limitations due to heterogeneity among 
patients with respect to preoperative treatment, race, gender, immune factors and other 
variables.  Studies using commercially available colon cancer cell lines offer several 
advantages. First and foremost is the reproducibility of cell lines. When minimizing the 
pass rate (the amount of times the cells are divided), early passes of cell lines behave 
nearly the same within that cell line across different experiments. This is important when 
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dealing with cancer cells that tend to divide rapidly and already behave differently than 
non-cancerous cells. With meticulous study and observation, after a few weeks, we know 
the behavior of the different cell lines under investigation. This is important because once 
their “normal” growth rate and behavior is known; it allows us to use external means to 
manipulate these cells to study different states to which cancer cells could possibly be 
exposed to in a patient. Although use of such cell lines is widely accepted they do have 
disadvantages. Cell lines are immortalized cancer cells. No matter what the conditions 
are; this will add caution to interpreting the results until these results are in turn tested in 
animal models or verified in a human clinical trial.  
 Not only do cell lines allow us to manipulate cancer pathology to investigate 
different aspects of cancer pathway progression, buy they also allow us to study these 
pathways in different stages of cancer. By utilizing well established immortalized CRC 
cell lines, we can examine different cancer stages. It allows us to look at benign non-
cancerous epithelial cell lines as well as cancer cell lines.   
 Prior to developing a hypothesis, screening arrays were performed utilizing Taq-
Man
®
 microfluidic technology array cards. In this screening, the overall goal was to 
establish which miRNAs were differentially dysregulated between cell lines of different 
cancer stages. The use of both an “A” card and “B” card was utilized, each assessing 384 
unique human miRNA (760 total miRNAs). Dukes A-D cell lines were screened and had 
a high number of these miRNAs expressed in each cell line (Table 14). Of the miRNAs 
expressed miRNA-99a and miRNA-100 had a unique expression that no other set of 
miRNAs had (Table 15). This differential expression led us to further investigate 
miRNA-99 and miRNA-100. 
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 Not to our surprise an extensive amount has been published regarding the 
miRNA-99 family, which includes miRNA-99a, -99b and -100. Specifically, a large 
amount of work has been done investigating the role of the miRNA 99 family and its 
suppression of prostate-specific antigen and cancer proliferation in prostate cancer.
112
 We 
investigated different pathways with which the miRNA 99 family was associated and 
noted its involvement in the mammalian target of rapamycin (mTOR) pathway. Although 
some work has been done previously with respect to the role of mTOR in colorectal 
cancer, there are few reports examining the effect of miRNA-99a mTOR protein 
expression and its ultimate effect on downstream targets of the mTOR pathway.   
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Table 14. Number of miRNAs expressed in screening array of cell lines ranging from 





Duke’s A Duke’s B Duke’s C Duke’s D
(SW1116) (SW480) (HT-29) (HCT116)
1st 384 
microRNAs
293 335 314 313
2nd 384 
microRNAs
262 219 209 210




Table 15. Fold Change and Regulation of miRNA 99 Family in the screening array for 



























miR-100 0.03 0.14 0.02 4.91 -39.5 -7.1 -52.3 4.9
miR-99a 0.02 0.14 0.03 4.85 -45.4 -7.0 -34.2 4.8




MAMMALIAN TARGET OF RAPAMYCIN (MTOR) SIGNALING PATHWAY 
miRNAs have been shown to be involved in multiple  pathways in all types of 
cancers; this is no different with colorectal cancer. One of the pathways that have been 
shown to influence cancer behavior, especially in prostate cancer, is the mTOR signaling 
pathway. Although much is known about this pathway and its two protein complexes, 
mTORC1 and mTORC2, there is still much to learn in regards to its relationships to CRC 
and its influence on CRC progression.  
Over the past several decades the mTOR, which is now referred to as the 
mechanistic target of rapamycin, mTOR signaling pathway (Figure 6) has been shown to 
play an integral role in the regulation of organ growth and homeostasis. Due to its 
regulation of multiple cellular processes, it has been shown to influence multiple cancer 
pathways, obesity and type 2 diabetes to name a few. This has led to much interest in 
further understanding this pathway in various disease states and particularly interest with 
respect to potential for pharmaceutical intervention in the mTOR pathway. 
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Figure 6. mTOR pathway 
 




TOR1 and TOR2 genes were identified in the early 1990s during genetic 
screening in budding yeast. These were shown to be mediators of the toxic effects of 
rapamycin on yeast. Rapamycin is a naturally occurring macrolide produced by 
Streptomyces hygroscopius bacteria. mTOR itself is a serine/threonine protein kinase that 
is part of the phosphoinositide 3-kinase (PI3K)-related kinase family and interacts with 
several proteins to form two distinct complexes aptly named mTOR complex 1(mTOR 
C1) and complex 2 (mTORC2). Not yet completely understood, the mechanism of action 
of rapamycins effect on mTOR is thought to occur by a gain-of-function complex when 
rapamycin binds intracellularly with the 12-kDA FK506-binding protein. It is believed 
that this rapamycin-FK506 complex will then interact with and inhibit mTOR protein 
when a part of the mTORC1 complex but does not inhibit the function of mTOR when it 
is a part of mTORC2. Although rapamycin-FK506 is implicated in this inhibition 
process, the exact binding process of this complex to mTORC1 has yet to be discovered. 
A. MTOR COMPLEX 1 (MTORC1) 
mTORC1 is composed of six protein components:  
1. mTOR protein 
2. mammalian lethal with sec-13 (mLST8, also called GBL)  
3. DEP domain containing mTOR-interacting protein (DEPTOR) 
4. Tti1/Tel2 complex  
5. Regulatory-associated protein of mammalian target of rapamycin (RAPTOR)  
6. proline-rich Akt substrate 40kDa (PRAS40)   
RAPTOR and PRAS40 are the two proteins that are unique to mTORC1, and are not a 
part of mTORC2.  
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 mTORC1 is involved in multiple key processes needed for health, not limited to 
but including protein synthesis, autophagy and lipid synthesis. This complex helps 
regulate downstream proteins that are key in protein synthesis. One of these being the 
eukaryotic initiation factor 4E (eIF4E)-binding protein 1 and the p70 ribosomal s6 Kinase 
1 (S6K1). Previously described, the phosphorylation of 4E-BP1 inhibits its binding to 
eIF4E, which then in turn promotes cap-dependent translation. In addition S6K1 is 
stimulated by mTORC1 and leads to its involvement in mRNA development, cap-
dependent translation and regulation of many other protein activities.  
Apropos autophagy, which is the degradation of cellular components by lysosomes, 
mTORC1 increases autophagy when it is inhibited. The opposite is true also, as when 
mTORC1 is stimulated by upstream inputs autophagy will decrease. This suggests that 
inhibition of TORC1 can lead to unregulated cell growth.   
B. MTOR COMPLEX 2 (MTORC2) 
mTORC2 is composed of seven protein components:  
1. mTOR protein  
2. mLST8  
3. DEPTOR 
4. Tti1/Tel2 complex  
5. Rapamycin-insensitive companion of mTOR (RICTOR) 
6. Mammalian stress-activated map kinase-interacting protein 1 (mSin 1)  
7. Protein observed with rictor 1 and 2 (protor 1/2) 
RICTOR, mSin1 and protor 1/2 are the 3 unique proteins that are a part of mTORC2.  
 
C. REGULATORS OF MTORC1 
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mTORC1 has multiple inputs from various upstream pathways. These currently 
include but are not limited to, growth factors, stress, energy status, oxygen availability 
and amino acids. These inputs lead to mTORC1's control on protein/lipid synthesis and 
autophagy.  
mTORC1 is regulated by growth factors that initially increase the phosphorylation 
of TSC2 via the protein kinase B (PKB) activation cascade. The activation of TSC2 in 
turn leads to inactivation of mTORC1. In addition extracellular-signal-regulated Kinase 
1/2 and S6K1 have the opposite effect and inhibit or deactivate the TSC1/2 complex that 
in turn leads to activation of TORC1.  
D. REGULATORS OF MTORC2  
 Compared to mTORC1, all aspects of the mTORC2 pathway, including its 
regulators are less well understood. Due to the inability of FKBP-12-rapamycin to bind to 
the intact mTORC2, it was originally thought that this complex was completely 
insensitive to rapamycin, however,  recently it has come to light that this is not the 
case.
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 The complex nature of mTORC2 is shown by the fact that some cells over time 
reduce mTORC2 signaling via suppression of mTORC2 assembly,  by an as yet not 
understood mechanism.
113
 Unlike mTORC1, mTORC2 is insensitive to upstream 
nutrients, yet responds to certain growth factors, including insulin. The mechanism of this 




 One facet of mTORC2 activity that is known is its effect upon AKT, which helps 
regulate certain cellular processes such as metabolism, growth, proliferation, metabolism 
and cellular survival. Sarbassov et al, in 2005 showed that mTORC2 phosphorylates 
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AKT at its hydrophobic motif, which results in its activation.
114
 In addition, it has been 
shown that silencing components of mTORC2 impairs the phosphorylation of some 





HYPOTHESIS AND SPECIFIC AIMS 
Several pathways that influence colorectal cancer have been shown to interact 
with the mTOR pathway such as the wnt pathway, PI3/AKT, P53 and RAS/RAF. These 
pathways influence normal cell life progression including apoptosis, tumor suppression, 
protein activation and cell binding to name only a few of their functions. Although 
mTOR has been shown to influence colorectal cancer, the link between the miRNA 99 
family and mTORs and its influence on CRC is not clear. It has been shown that certain 
miRNAs bind to mTOR, however, changes in the cells’ activity, and downstream protein 
expression have not yet been fully described.  
Preliminary work in our laboratory has shown the miRNA 99 family miRNA to 
be differentially expressed among colon cancer cell lines of different metastatic potential, 
suggesting that these miRNA may play a role in invasiveness and metastasis in CRC. 
This was investigated with the following hypothesis:  
Hypothesis:  miR-99a decreases cell proliferation, migration and possibly invasion 
of colorectal cancer cell lines by decreasing mTORC1 and mTORC2 
expression. 
3 Specific Aims will be investigated: 
1. To determine the effect of miRNA-99a on mTOR protein phosphorylation
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2. To determine miRNA-99a’s influence on the phosphorylation of mTOR 
pathway’s downstream proteins: S6K1and 4EBP1 
 
3. To determine if transfection of HT-29, HCT-116 and CCD841 cell lines with 




MATERIALS AND METHODS: 
A.   CELL LINES 
 In this study, three relevant cell lines (Table 1) acquired from American Type 
Culture Collection (ATCC, Manassas, Virginia) were reinitialized from frozen (-80°C) 
material, then either allowed to grow for future testing, i.e. Western blot analysis, 
polymerase chain reactions (PCR) or immunohistochemistry (IHC), or grown for 
harvesting to be used at a later time.  All cell lines were adhesive in nature and are not 
free floating cell lines, i.e. when cells are growing and dividing they adhere to the cell 
culture flasks. 
1. CCD 841 CoN (ATCC® CRL-1790™)  
Normal epithelial colon cells were harvested from a human female fetus at the 21 
week gestation period and cultured in Eagle’s Minimum Essential Medium 
(EMEM) supplemented with 0.5% mixture of penicillin, streptomycin, 
amphotericin B, 0.5% L-glutamine, and 10% Fetal Bovine Serum (FBS). 
2. HT-29 (ATCC® HTB-38™) 
Dukes’ type C primary colorectal adenocarcinoma epithelial cells were harvested 
from a 44 year-old woman and cultured in McCoy’s 5A medium supplemented 
with 0.5% mixture of penicillin, streptomycin, amphotericin B, 0.5% L-
glutamine, and 5% FBS. 
3. HCT-116 (ATCC® CCL-247™) 
Dukes’ type D, primary colorectal carcinoma epithelial cells were harvested from 
a man (age not stated), and cultured in McCoy’s 5A medium supplemented with 
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0.5% mixture of penicillin, streptomycin, amphotericin B, 0.5% L-glutamine, and 
5% FBS. Notably it has come to light that this cell line is not a typical 
adenocarcinoma Dukes’ D cell line but from a patient with Hereditary 
Nonpolyposis Colorectal Cancer (HNPCC), which is a type of cancer that is 
defective in DNA mismatch repair, which will lead to microsatellite instability. 




B. MAINTENANCE OF CELL LINES  
Each cell line was maintained in a cell culture hood, which was swabbed down 
with 70% ethanol (EtOH) before and after each use and the hood was run for 10 minutes 
prior to working to establish protective air flow. All items, including gloved hands, 
entered the hood only after being cleansed with 70% EtOH. Only one cell line and 
appropriate culture medium were placed in the cell culture hood at any given time and the 
hood was cleaned with 70% EtOH in between cell line transfers. 
1. INITIAL CULTURING OF CELLS  
For each cell line, 8mL of appropriate culture media was first added to a 15mL 
tube. Then 9mL of appropriate culture media was added to a 25 mL cell culture flask. 
The flask was incubated to allow temperature equilibration of the culture media prior to 
placing the freshly thawed cells into the flask. The vial of frozen cells was then rapidly 
thawed in a 37°C water bath, keeping the O-ring and cap out of the water to reduce 
contamination. After the cells were thawed, the external surface of each vial was cleansed 
with 70% EtOH, placed in the hood and transferred to the 15mL tube with appropriate 
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culture media. Finally, the flask with the thawed cells is rinsed using 1 mL of appropriate 
culture media and added to the 15 mL tube. The contents of the 15mL tube were 
centrifuged at 125g, at 37°C for 6 minutes, until a cell pellet was formed. The cell pellet 
was aspirated and then resuspended using 1mL of appropriate culture media via a 
micropipette tip to obtain cell suspension. The cells were then added to the pre-warmed 
25 mL flask with 9 mL of appropriate culture media which was gently rocked in order to 
disperse cells and then was placed back in the incubator at 37°C, where they were left to 
grow with daily monitoring.  
2. SUB-CULTURING/SPLITTING CELLS  
Prior to sub-culturing or splitting cell lines, the current flask of actively growing 
cell lines was viewed at 10x magnification to determine whether the cells were 70-90% 
confluent and ready to be divided. When the cells were determined to be proper 
confluent, they were then transferred from the incubator into the cell culture hood. For 
each cell line the appropriate culture media and a 3 mL aliquot of trypsin-EDTA were 
then set into a 37°C water bath to thaw. Once thawed, the 15 mL tube of trypsin-EDTA 
and bottle of cell culture medium were vortexed and homogenized, then the containers 
were cleaned with 70% EtOH and placed in the cell culture hood. With the culture flask 
inside the cell culture hood, the next step was to remove the old culture medium from the 
flask and discard it into the waste beaker. The flask was then washed with 0.5mL of 
trypsin for 2-3 seconds and then emptied into the waste beaker. Next, 2.5 mL of trypsin 
was added to the flask, gently rocked and the flasks were observed through an inverted 
microscope to determine when the cells had rounded up into the trypsin media off the 
bottom of the flask. The type of cell line, as well as confluence of the cells, has an effect 
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on how fast the trypsin works. While the trypsin acted on the old culture flask, the 
appropriate cell culture medium was added to a new 75 mL flask(s) and incubated at 
37°C. Once the trypsin exerts its effect, the cells are rounded up and suspended; 8mL of 
appropriate culture media was added to the flask. This cell suspension was added to a 
15mL tube and then centrifuged at 125g, at 37°C for 6 minutes, until a new cell pellet 
was formed. This 15mL tube was then cleaned with 70% EtOH and placed back into the 
cell culture hood. The supernatant was discarded and the cell pellet was re-suspended 
using 1mL of appropriate culture media via a micropipette tip to obtain a single-cell 
suspension. 
 At this point, cells were counted using a hemocytometer for further experiments 
or divided in pre-determined ratios for sub-cultivation. The split ratios for each cell line 




Table 16. Cell line criteria for each passage 
Cell Line: Subcultivation* Ratio: Medium Renewal per 
week: 
Number of cells 















1:3 – 1:10 2-3 times ≥1-2 x 10
6
 
    
   
 
    





The calculated amount of cells was then added to the new 75 mL flask with pre-
warmed (37°C) culture media. Finally, the flask with cells in suspension was labeled with 
cell line name, passage number and date, then gently rocked and returned to the 
incubator. 
3. SUBSEQUENT FREEZING OF CELLS 
The appropriate cryo-medium was created by taking a cell lines’ respective 
medium and adding 5% sterile dimethyl sulfoxide (DMSO) to the final concentration. 
Similar to the sub-culturing/splitting protocol, the cells were treated with trypsin-EDTA, 
collected in media, and the cell suspension centrifuged into a pellet. However, as opposed 
to re-suspending the cell pellet in normal cell culture media, cryo-media was used. The 
cells were counted and the concentration of cells was adjusted to 4 x 10
6
 cells/2mL of 
cryo-media. 2mL of the suspension was added to cryo-flasks that were specifically 
labeled. The cryo-flasks were stored in an ethanol-bath at -80°C overnight and then 
transferred into liquid nitrogen the next day. The earliest possible passage to obtain 
freezes is passage number 3. 
C. MIRNA TRANSFECTION 
Once the cell suspension’s concentration was determined, the cells were plated 
into separate wells on a 6-well plate at a concentration of 250,000 cells/2mL culture 
media and then allowed a 24-hour period to adhere to the plate prior to transfection. At 
24 hours, transfection of the following was performed:  
 miR-99a mimic 
 miR-99a antagomir 
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 mimic negative control 
 antagomir negative control 
 mimic positive control  
 antagomir positive control  
These were introduced to different individual wells using the Lipofectamine
®
 3000 
Transfection Reagent Protocol. Each cell line was incubated for 72 hours after 
transfection prior to cell harvesting. 
D. HARVESTING CELLS (FOR RNA OR PROTEIN)  
After isolated cell populations had been transfected or treated with rapamycin, 
they were harvested for either total RNA or protein content. The medium was aspirated 
carefully and discarded. The cells were rinsed once with ice cold phosphate-buffered 
saline (PBS) and cells were then treated with trypsin-ethylenediaminetetraacetic acid 
(EDTA). This allows for them to round up in the appropriate media when added to the 
plate. The cell suspension was then centrifuged at 125g for 6 minutes at 37°C until a 
pellet was formed. The cell pellet was re-suspended with 1mL of 1x PBS and centrifuged 
into a pellet. If harvesting for total RNA, the cells were re-suspended using 0.4 mL of ice 
cold lysis buffer. If harvesting for protein, the cells were re-suspended using 0.15 mL of 
ice-cold radio immune-precipitation assay (RIPA) buffer. The cells and buffer are mixed 
thoroughly by pipetting and then stored at -80°C until needed. 
 
E. POLYMERASE CHAIN REACTION 
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Cell samples in lysis buffer were prepared first via reverse transcription for 
microRNA quantification using a Step-One™ RT-PCR
® 
System with default long 
thermal cycling conditions. Using the TaqMan miRNA reverse transcription kit and 
TaqMan microRNA-specific primer pool (5x), targeted RNA was converted into cDNA 
in a thermal cycler. TaqMan probes (20x) were used to bind to complementary sequences 
on target cDNA during quantitative RT-PCR. The levels of miRNA-99a were normalized 
to miRNA RNU6, an endogenous internal reference, in order to calculate ΔCT values.  
ΔCT values of samples transfected with miRNA-99a mimic and antagomir were 
compared to the ΔCT values of corresponding positive and negative controls. 
F.  WESTERN BLOT 
For protein quantification, western blots (n=4 for each protein) were performed 
for target proteins in the mTOR pathway (Table 16). After the sample was thawed on ice 
from its -80°C storage, 0.001 mL of protease inhibitors were added. The cells were then 
sonicated to disrupt cellular membranes. The cell debris was centrifuged into a pellet. To 
determine the total concentration of protein in the sample, a bicinchoninic acid (BCA) 
assay was performed. The supernatant of the sample was then diluted by a factor of 20 
with double distilled water in a 96 well plate. For reference, concentration standards from 
0 to 1000ng/µL were added to appropriate wells. All wells were then treated with 
0.16mLs of BSA assay and allowed to incubate at 37°C for 30 minutes. After incubation, 
the plates were then analyzed using Titertek Multiskan MCC/340
®
 microplate reader 
which produced protein concentration of the samples in question. 
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 An appropriate percentage Bolt
®
 Bis-Tris Plus Gel was placed in the Bolt
®
 Mini 
Gel Tank which was then filled half-way with running buffer. The wells were then loaded 
with molecular marker standards and cell protein samples ranging from 40 to 100 
micrograms. Finally the remainder of the tank was filled with running buffer. The gels 
were run at 165mV for 35-90 minutes to run the molecular markers off the gel depending 
on the size of the protein of interest.  
Proteins of interest in the mTOR pathway, their molecular weight (MW), and 




Table 17. mTOR pathway proteins of interest with molecular weight and predicted 
Western Blot band detection size.  
 
 
Protein Observed Molecular Weight 
(kDa) 
Predicted Band Size (kDa) 
mTOR 289 >250 
RAPTOR 149 149 
RICTOR 192 192 
eIF4g1 175 220 
S6K1 70 70 and 85
123
 





The completed gel with separated proteins is then transferred onto a 
Polyvinylidene difluoride (PVDF) membrane using the iBlot
®
 Gel Transfer Device 
(protocol reference). The PVDF membrane was then cut to an appropriate size, covered 
in 5% milk, and rocked for 1 hour at room temperature in order to block proteins. 
Primary antibodies for target proteins were prepared in 5% milk and poured over the 
membrane which was then rocked for another 1 hour at room temperature.  The 
membrane was washed for 10 minutes with Tris-buffered Saline and Tween 20 (TBS-T), 
and then covered with the secondary antibody which was also prepared in 5% milk and 
rocked for 1 hour at room temperature. The membrane was again washed for 10 minutes 
with TBS-T.  
 1-1.5mL of Enhanced chemiluminescence (ECL) reagents A and B, which react 
with the horseradish peroxidase (HRP) enzyme on the secondary antibody to produce 
light, was applied to each membrane in order to detect the target protein. The membrane 
and ECL substrates were left in the dark room for 2 minutes before the excess ECL was 
removed and the membrane was placed in a plastic cassette and left in the dark room.  
G. CELL MIGRATION ASSAY 
 To determine the migration properties of the cell lines themselves Boyden 
chamber assays were utilized. Five assays were performed for each cell line. First 
described by Boyden in 1962, these assays allow for the cells chemotactic behavior to be 
determined.
124
 This assay separates two chambers with a microporous membrane (8 μm 
pore size). After transfection has occurred the cells under study are then seeded into in 
the upper chamber. In this step the cells can be “starved” to a certain degree. In all assays 
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used in my studies, the FBS percentage was reduced from 10%, which is the percentage 
we use in day to day maintenance, down to 1% in this assay. This helps to promote cells’ 
movement, once they have been starved for a period of time. They are allowed to settle in 
this chamber for 24 h without chemoattractant added to the bottom chamber. 24 hours 
after plating the cells into the upper chamber the addition of media with 20% FBS is 
added to the bottom chamber. Then the cells are allowed to migrate for 12 h. (Figure 7) 
At the 12 h mark the cells are observed under light microscopy and then stained to allow 
for quantification in a plate reader. The cells were stained with Blue Cell Stain Solution 









H. CELL INVASION ASSAY 
 Similar to the Boyden migration assay, the invasion assay now coats the 
microporous membrane (8 μm pore size) with a uniform layer of dried basement 
membrane matrix solution. This layer allows for discrimination between invasive and 
non-invasive cells. If the cells have invasive properties then they will be able to degrade 
this matrix membrane solution and then migrate through the 8 μm pores that are present 
in the polycarbonate membrane inserts. (Figure 8) Similar to the migration assay, the 
cells are allowed 24 hours to settle after plating into the upper chamber. The upper 
chamber cells are once again “starved” with 1% FBS containing media. At the 24 hour 
time point, 20% FBS containing media is added to the bottom chamber. At the 12 hour 
mark the cells that have migrated are stained and the utilization of the plate reader at 
560nm is used to determine the amount of cells that migrated. Five assays were 









I.  STATISTICAL ANALYSIS 
 To analyze statistical significance of the Western blot assays and 
migration/invasion studies we utilized the unpaired t-test. All data was analyzed in SPSS, 
(SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, SPSS Inc.) using 
a two tailed analysis. All sample sizes were equal and had a normal distribution. 
Statistical significance was defined as a p ˂ 0.05.  
 For Western Blot samples all data had a sample size equal to four, unless noted. 
These were four cell culture samples that were each grown from new freezes, transfected 
at the same pass generation and transfected in the same fashion to give a true sample size 





TRANSFECTION OVERVIEW, PRELIMINARY RESULTS AND DISCUSSION 
A.  INTRODUCTION 
Transfection is the process of introducing an external nucleic acid into the normal 
functioning cell. In our experiments we utilize two types of non-viral transfection. The 
use of mimic and antagomirs were used to accomplish our goals. Mimic transfections 
occur when the investigator introduces more of what we are trying to upregulate. In our 
experiments with miRNA-99a, by introducing miRNA-99a mimics we are increasing the 
amount of active miRNA-99a into the cell’s cytoplasm. The opposite occurs when we 
introduce an antagomir into the cell’s cytoplasm.  miRNA-99a antagomir ultimately 
down regulates the available amount of active miRNA in question.  
 Transfecting antagomirs tend to be more finicky and less successful than mimic 
reactions as it is more difficult to completely eliminate a resource from a cells 
environment than it is to add to it.  
The use of miRNA mimics and antagomirs in transfection experiments allows us 
to manipulate cell line behavior and protein expression. Once transfection had occurred 
the first step is to verify the success or failure of the transfection.
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B. DATA AND RESULTS 
 Real time polymerase chain reaction (qRT-PCR) is used to verify successful or 
unsuccessful transfection.  Initially HT-29 cell line was investigated. HT-29 was allowed 
to grow and when appropriate amounts of cells were available seeded into 6 well culture 
plates.  After 24h, after proper seeding and settling of transfection with miRNA-99a 
mimic, mimic negative control, antagomir and antagomir negative control was 
performed. We used Lipofectomine 3000
®
 following manufacture’s protocol. This was 
repeated with CCD841 and HCT116 cell lines.  
 Data regarding transfection of HT-29 is shown in Figure 9. The mi-RNA99a 
mimic transfection was associated with a fold change of miRNA 99a expression of 8750 
as compared to  the antagomir transfection which was associated with a miRNA 99a fold 
change of 0.065 (fold regulation of 15.2).  
 Next HCT-116 cell line was transfected, and verified via qRT-PCR. HCT-116 
showed an increase in miRNA-99a expression as compared to the non-transfected 
control, however, the antagomir was closer to baseline expression and not down regulated 
(Figure 10).  
 After successful transfection of HT-29 and HCT-116, our attention turned to the 
transfection of CCD 841 (normal colon epithelial cells). Once again successful 
transfection was verified via qRT-PCR, and is shown in Figure 11. Similar to HCT-116 
transfection, CCD 841 cells exhibited a fold change in miRNA 99a expression of 34 with 
transfection of miRNA-99a mimic. Transfection with the antagomir was not as 
successful. We observed a fold change of 1.4 in miRNA 99a expression, which is 
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opposite of what we would expect, ie. a down regulation with the introduction of an 





Figure 9. HT-29 Fold Change of miRNA-99a Expression after Transfection (n=2)  






Figure 10. HCT-116 Fold Change of miRNA-99a Expression after Transfection (n=2)  






Figure 11. CCD-841 Fold Change of miRNA-99a Expression after Transfection (n=2)  




C.  DISCUSSION 
The process of transfection allows the investigator to up- or down-regulate certain 
elements of cell lines so we can investigate the effects they have on the cells. In this case, 
we wish to investigate how the expression of miRNA-99a affects cell protein expression 
and ultimately motility and invasion. Key to this process is verification that successful 
transfection has occurred.  
 These data suggest that in HT-29, transfection of miRNA-99a was successful with 
both the mimic and antagomir. The fold change for the mimic was well over 1000.  In 
addition, the antagomir transfection of miRNA-99a in HT-29 resulted in down regulation 
of miRNA 99a expression. This was the only cell line in which the antagomir actually 
showed downregulation as compared to the negative control.  
 Although the fold change observed in HCT-116 was not to the same degree as 
with HT-29, it was also upregulated in comparison to the negative control. The antagomir 
did not show down-regulation of miRNA 99a expression when compared to the negative 
control. 
When investigating the CCD 841 (normal epithelial cell line), the transfection 
data were not as satisfactory as for HT-29 and HCT-116.  While transfection with the 
miRNA 99a mimic did result in a mild upregulation in miRNA 99a expression as 
compared to the negative control, this was relatively small, only a fold change of 38. This 
is the trend that we expected but when compared to the CRC cell lines the transfection 
did not demonstrate an impressive fold change.   
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However, successful transfection of the mimic occurred in all three cell lines 
allowing us to proceed with further analyses. Less promising results occurred with the 
antagomir. Although, HT-29 showed a negative fold regulation, CCD-841 and HCT-116 
minimally exceeded zero. This is not surprising as it is somewhat difficult to completely 
block the activity of naturally occurring miRNAs in the cell. One possible solution to this 





WESTERN BLOT STUDIES 
 In order to study the effect of miRNA 99a upon the mTOR pathway it is 
necessary to study proteins that mTOR has an effect on. We chose to do this utilizing 
western blot analysis. The mTOR pathway has several proteins of interest that can be 
investigated, mTOR itself along with RAPTOR, RICTOR, S6K1, ieF4EG-1 and 
eiF4EBP-1 to name a few. The complexity of the mTOR pathway can be seen in Figure 
12, which only shows the input of AKT into mTORC1. As stated in the introduction, 
mTOR has many pathways that converge on mTORC1 and which ultimately influence 
several vital processes in protein production and cell motility.  
 Part of the difficulty, when investigating the mTOR pathway, is dealing with the 
active forms of the protein. In some cases, the phosphorylation will activate the protein 
whereas in other cases, phosphorylation will inactivate the protein. This is demonstrated 
with the phosphorylation of 4EBP1. When 4EBP1 is phosphorylated directly via 
mTORC1, it inactivates 4EBP1. The same occurs when 4EBP1 is phosphorylated directly 
by MSK1. This becomes confusing as 4EBP1 can also be inactivated by PP2A catalytic, 
as shown in Figure 13.  
 PP2A catalytic is somewhat of a regulator between 4EBP1 and p70 S6 Kinase 1 
(S6K1). mTORC1 phosphorylates both proteins, but in each case acts differently. 4EBP1
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 when phosphorylated is inactivated, but when TORC1 phosphorylates S6K1 it is 
activated. Then PP2A catalytic comes into play. It dephosphorylates both S6K1 and 
4EBP1, but when it does this it activates 4EBP1 and inactivates S6K1. This is seen in 
Figure 13, where the red +P indicates that phosphorylation inactivates the protein and the 
green -P indicates that dephosphorylation activates the protein. In addition the red - P 
indicates that dephosphorylation inactivates the S6K1.  
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Figure 12. Mechanistic Target of Rapamycin Pathway focusing on AKT input into 
mTORC1 
 




Figure 13. mTOR pathway focusing on mTORC1 output on S6K1 and 4EBP1 (enlarged 
central portion of Figure 11) 
 





 Prior to investigating the effects that miRNA-99a had on the mTOR pathway 
itself, we wanted to witness what the cells response to direct rapamycin dosing would do. 
To initially do this we wanted to establish a dosing curve to recognize the optimum dose 
of rapamycin that would kill 50% of the cells alive in culture.  
 We utilized MTT assay to establish this curve and the results are shown in Figure 
14. After multiple attempts with different concentrations of rapamycin to decrease the 
cell culture growth, we found that rapamycin directly did not reliably decrease the 







Figure 14. MTT assay dosing curve of increasing Rapamycin dosing concentrations in 
HT-29, HCT-116 and CCD-841. Two different concentrations of plated cell 






SPECIFIC AIM 1: TO DETERMINE THE EFFECT OF MIRNA-99A’S ON MTOR 
PROTEIN PHOSPHORYLATION 
A. INTRODUCTION 
Initially we intended to investigate mTOR, RICTOR and RAPTOR proteins and 
determine if transfection with miRNA-99a would change their expression. However as 
the RICTOR and RAPTOR proteins are part of the mTOR complex, we chose instead to 
focus our investigations on the levels of mTOR itself and not the individual proteins of 
these complexes. It has not, to our knowledge, been shown whether the phosphorylation 
or dephosphorylation of RICTOR or RAPTOR changes the activity of mTORC1 or 




The decision was made to investigate direct levels of mTOR protein and several 
of the downstream proteins that the mTOR pathway has been shown to influence.  These 
proteins include S6K1, 4EBP1 and eIF4G1. These proteins were investigated in HT-29, 
HCT-116 and CCD-841 cell lines. We chose to limit our study to cell lines derived from 
cancers with regional and distant metastasis as this would allow us to study changes in 
protein expression that may correlate with significant survival differences seen in these 
cancer stages clinically and therefore be possible targets for therapeutic intervention. 
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B. DATA AND RESULTS 
To answer specific aim 1, we needed to determine the effect of miRNA-99a upon 
mTOR protein itself. To do this we utilized Western blot assay after transfection of the 3 
cells lines with miRNA-99a mimic. 
Initially CCD-841 (normal epithelial CRC cells) underwent Western Blot 
analysis. Both antibodies for total mTOR and phosphorylated only had a similar trend 
showing downregulation after transfection compared to the negative control.   
When the Western Blots were analyzed for mTOR total after transfection with 
miRNA99a, the CCD-841 showed a relative density of 0.022 ± 0.013 (Figure 15). When 
compared to the negative control which resulted in a relative density of 0.081 ± 0.051. 
This was not statistically significant with p = 0.14. 
 Similarly, CCD-841 relative density from Western Blot analysis of 
phosphorylated mTOR after miRNA-99a mimic was transfected resulted in a value of 
0.04 ± 0.01(Figure 16). This is compared to the negative control after transfection which 
resulted in a value of 0.06 ± 0.01. This was not statistically significant with a p value 
equal to 0.19. Although not statistically significant, with n=4 all Western Blots studied 
had the same trend. When investigation the normalized percentage of total antibody and 




Figure 15. Western blot and bar graph of total mTOR protein expression when miRNA-
99a mimic is transfected in normal epithelial colon cell line CCD-841. Bar 
chart is expressed in relative density units.  
         
 
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Figure 16. Western blot and bar graph of phosphorylated mTOR protein expression when 
miRNA-99a mimic is transfected in normal epithelial colon cell line CCD-
841. Bar chart is expressed in relative density units.  
      
              
 
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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 HT-29 was then investigated. We probed the transfected cells for both 
phosphorylated and total mTOR protein expression. We observed a relative density 
expression of 0.06 ± 0.02 relative density units for phosphorylated mTOR when 
compared to beta actin following transfection with miRNA-99a. This was not statistically 
significant (p = 0.07) when compared to the negative control (0.15 ± 0.05), yet with an n 
= 4 the trend of downregulation was consistent.  These results are shown graphically in 
Figure 17. Probing for total expression of mTOR in HT-29 cell line was unsuccessful 
despite using 16 different mTOR antibodies; this could be due to non-specific binding of 
antibodies to other proteins. When investigation the normalized percentage of total 





Figure 17. Western blot and bar graph of phosphorylated mTOR protein expression when 
miRNA-99a mimic is transfected in HT-29 CRC cell line. Bar chart is 






99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Finally we investigated phosphorylated and total mTOR expression after miRNA-
99a transfection in the HCT-116 cell line. Although not significant, probing for mTOR 
total had the same trend as when we probed for the phosphorylated only mTOR(Figure 
18). Similarly to HT-29, transfected cells with miRNA99a were downregulated compared 
to the negative control.  This downregulation was statistically significant when probing 
for phosphorylated mTOR but not total mTOR (Figure 18-19). When investigation the 
normalized percentage of total antibody and phosphorylated compared to the negative 





Figure 18. Western blot and bar graph of total mTOR protein expression when miRNA-
99a mimic is transfected in HCT-116 CRC cell line. Bar chart is expressed in 
relative density units.  
         
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Figure 19. Western blot and bar graph of phosphorylated mTOR protein expression when 
miRNA-99a mimic is transfected in HCT-116 CRC cell line. Bar chart is 
expressed in relative density units.  
 
       
 
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)




 In order to answer specific aim 1, we needed to limit our focus to miRNA-99a’s 
effect on the total and phosphorylated mTOR protein levels after transfection.  We 
expected, with the introduction of miRNA-99a mimic, the expression of phosphorylated 
mTOR protein would decrease in comparison to the mimic negative control. This trend 
was observed in all three cell lines under study.  
 HCT-116 when probing for phosphorylated only mTOR was the only cell line 
statistically significant. Although this may be the case, all of the above studies had a 
similar trend which was promising for future experiments.   
 We then investigated total mTOR protein expression after transfection of miRNA-
99a mimic. This was successful in HCT-116 and normal epithelial cell line CCD-841, but 
we were unable to optimize an antibody for Western Blot detection with the HT-29 cell 
line. This could be due to lack of interaction with that particular primary antibody or 
mTOR not being expressed readily in that particular cell line. The latter is unlikely as 
phosphorylated mTOR was detected in this same cell line. The data for HCT-116 and 
CCD-841 reaffirmed our results from the phosphorylated-mTOR data and suggest that 
when miRNA-99a is introduced into the cell culture environment, there is a resulting 




SPECIFIC AIM 2: THE EFFECT OF MIRNA-99A’S EFFECT ON S6K1 AND 4EBP1 
A. INTRODUCTION 
Our attention now focused on downstream proteins of the mTORC1 complex. The 
ultimate goal being to answer specific aim two, which was to determine the effect of 
miRNA-99a on the phosphorylation of mTOR pathway’s downstream proteins. Initially, 
we performed Western blot analysis of phosphorylated S6K1 and total S6K1 expression 
in HT-29 cell line, followed by evaluation of cell lines HCT-116 and CCD-841. The 
same was then performed for 4EBP1. 
B. DATA AND RESULTS 
1. S6K1 
Initially CCD-841, normal epithelial cell line, showed the expected result of 
downregulation after transfection with miRNA-99a. After transfection, S6K1 relative 
density expression was 0.018 ± 0.007 compared to the negative control 0.026 ± 0.008 
(Figure 20). This comparison was statistically significant with a p value equal to 0.008. 
When investigation the normalized percentage of total antibody and phosphorylated 
compared to the negative control, this resulted in 70% and 75% respectively. 
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Figure 20. Western blot and bar graph of phosphorylated S6K1 (75 KDa) protein 
expression when miRNA-99a mimic is transfected in normal colon epithelial 
cell line CCD-841. Bar chart is expressed in relative density units. 
                     
 
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
103 
 
HT-29 cell line was then transfected with miRNA-99a, and then mTOR total was 
probed for in the Western Blot studies. This resulted in a significant difference (p = 0.02) 
between miRNA-99a mimic and its transfected negative control (Figure 21). Once again 
the same pattern was observed after transfection, a downregulation of S6K1 compared to 
negative control.  
Finally, HT-29 cell line was transfected with miRNA-99a and probed for 
phosphorylated only S6K1. This resulted in Western Blot analysis that showed a relative 
density measurement of 0.19 ± 0.04. This was compared to the transfected negative 
control which resulted in a relative density of 0.22 ± 0.07 (Figure 22). This was not 
statistically significant (p = 0.15) but all samples had the expected downregulation of 
S6K1 after transfection when compared to the negative control.  When investigation the 
normalized percentage of total antibody and phosphorylated compared to the negative 





Figure 21. Western blot and bar graph of total S6K1 (70 KDa) protein expression when 
miRNA-99a mimic is transfected in HT-29 CRC cell line. Bar chart is 
expressed in relative density units.  
         
 
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)




Figure 22. Western blot and bar graph of phosphorylated S6K1 (70 KDa) protein 
expression when miRNA-99a mimic is transfected in HT-29 CRC cell line. 
Bar chart is expressed in relative density units. 
    
 
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Once again we investigated both HCT-116 and CCD-841 for S6K1. The antibody 
probes were successful only when probing for phosphorylated antibodies and were not 
successful for total expression.  HCT-116 phosphorylated resulted in a different pattern 
than expected. When transfected with miRNA-99a mimic it was upregulated (0.09 ± 
0.02) compared to the negative control (0.06 ± 0.02, Figure 23). Although not statistically 
significant (p = 0.11) this was an interesting result as it happened in all 4 samples and 
was the first experiment that showed this type of pattern after transfection. When 
investigation the normalized percentage of total antibody compared to the negative 
control, this resulted in 164% change. 
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Figure 23. Western blot and bar graph of phosphorylated S6K1 (70 KDa) protein 
expression when miRNA-99a mimic is transfected in HCT-116 CRC cell line. 
Bar chart is expressed in relative density units. 




99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)




Figure 12 shows the mTORs pathway direct interaction with 4EBP1. When 
mTOR is active and phosphorylates 4EBP1 it turns 4EBP1 off, this is the opposite of 
what mTOR does to the protein S6K1. Now that S6K1 was elucidated in the cell lines 
under study, we next wanted to see how miRNA-99a would influence the 
phosphorylation of 4EBP1.  
First CCD-841 underwent Western blot analysis for 4EBP1 after transfection with 
miRNA-99a.  The phosphorylated only Western Blots resulted with the same average 
across 4 samples (Figure 24). Both the negative control (0.16 ± 0.09) and transfected cell 
lines (0.16 ± 0.11) basically showed no difference. 
Investigating total expression we saw upregulation of 4EBP1 after transfection 
with miRNA-99a compared to negative control (Figure 25).  After transfection with 
miRNA-99a, a relative density of 0.14 ± 0.12 resulted compared to the negative control 
equal to 0.18 ± 0.14. Once again the p value was not statistically significant but it was 
approaching significance (p = 0.06). When investigating the normalized percentage of 
total antibody and phosphorylated compared to the negative control, this resulted in 78% 





Figure 24. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein 
expression when miRNA-99a mimic is transfected in normal colon epithelial 
control cell line CCD 841. Bar chart is expressed in relative density units. 
   
 
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Figure 25. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression 
when miRNA-99a mimic is transfected in normal colon epithelial control cell 
line CCD 841. Bar chart is expressed in relative density units. 
   
 
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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After this, HT-29 was transfected with miRNA-99a and then underwent Western 
Blot analysis for total and phosphorylated only relative density measurements of 4EBP1. 
Figure 26 shows the results of phosphorylated only 4EBP1, which is 0.46 ± 0.11 for 
miRNA-99a mimic compared to the negative control, 0.42 ± 0.09. This was not a 
statistically significant comparison with p = 0.28 for our 4 samples but once again all had 
a similar trend. 
Next, probing for total expression of 4EBP1 shows a similar upregulation 
compared to negative control trend, although it is still not statistically significant (p = 
0.28). After miRNA-99a transfection the relative density average was 1.17 ± 0.87 
compared to the negative control average of 0.87 ± 0.60 (Figure 27). When investigation 
the normalized percentage of total antibody and phosphorylated compared to the negative 





Figure 26. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein 
expression when miRNA-99a mimic is transfected in HT-29 cell line. Bar 
chart is expressed in relative density units.  
 
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Figure 27. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression 
when miRNA-99a is transfected in HT-29 cell line. Bar chart is expressed in 
relative density units. 




99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Once again after elucidating the trend in Dukes C CRC cell line, our attention 
next focused on HCT-116, Dukes’ D cell line. After transfection, Western Blot analysis 
showed a relative density of 0.21 ± 0.11 compared to the negative control 0.24 ± 0.04 
(Figure 28). Similarly the antibodies that detected total protein expression and not just 
phosphorylated had a similar trend with the mimic being downregulated (1.61 ± 0.27) 
compared to the negative control (1.78 ± 0.36, Figure 29). Both of these sets of Western 
Blots were not statistically significant with p values of 0.31, 0.25 respectively but all had 
a similar trend. This is interesting because this trend is the exact opposite of the Dukes’ C 
and normal epithelial cell lines when probing for not only 4EBP1 but also S6K1. Finally, 
when investigating the normalized percentage of total antibody and phosphorylated 




Figure 28. Western blot and bar graph of phosphorylated 4EBP1 (15-20 KDa) protein 
expression when miRNA-99a mimic is transfected in HCT-116 cell line. Bar 
chart is expressed in relative density units.  
   
 
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)
CON+ Purchased positive control cell lysate
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Figure 29. Western blot and bar graph of total 4EBP1 (15-20 KDa) protein expression 
when miRNA-99a mimic is transfected in HCT-116 cell line. Bar chart is 
expressed in relative density units.  
   
 
  
99M mIR 99a Mimic transfected
99A mIR 99a Antagomir transfected
M- mIR 99a negative mimic transfected (Mimic Sham)
A- mIR 99a negative antagomir transfected (Antagomir Sham)




 In our study, we focused only on HT-29 and HCT-116 cell lines as well as one 
normal colon epithelial cell line. This decision to limit our study to these two cell lines 
can be justified as our ultimate goal is to uncover the mTOR pathways’ influence on 
CRC metastatic potential. By focusing on these two cell lines, it allows us to limit our 
study to cell lines that are defined by their metastatic properties, HT-29 being derived 
from a cancer characterized by regional metastasis and HCT-116 derived from a cancer 
characterized by distant metastasis.  
 Our first step when investigating the mTOR pathway is to initially see if mTOR 
protein itself is affected when miRNA-99a is transfected into the cell line. It has been 
shown that miRNA-99a directly interacts with mTORC2 complex.
126
 miRNA-99a has 
been shown to directly bind to this complex and repress its expression.  We showed 
through Western blot analysis that transfection of miRNA-99a does indeed reduce the 
amount of both total and phosphorylated mTOR protein in all studied cell lines. Once this 
was established our focus turned to addressing specific aim two.  
In order to answer specific aim two, we queried downstream effectors of 
mTORC2. Once we established that miRNA-99a had an effect on the overall expression 
of the active or phosphorylated  form of mTORC1 and mTORC2  we wished to see what 
effect this down-regulation had on the proteins that mTORC1 directly targets. Initially we 
investigated the effect of miRNA-99a on S6K1.  
 One of the key roles of mTORC1 and its interaction with S6K1 is the regulation 





 After we noted the effects that miRNA-99a had on the mTOR protein 
itself, it was key to study the phosphorylation or de-phosphorylation of S6K1. It has been 
shown in other cancers and disease states that when mTORC1 is active, it phosphorylates 
S6K1, which is thereby activated.   
 In our experiments, we would predict that if mTOR phosphorylation would be 
down-regulated as compared to the negative control, we would expect S6K1 to also to be 
down-regulated. This is what occurred in the HT-29 cell line as well as in CCD-841. In 
addition, in the HT-29 cell line total S6K1 was down-regulated as compared to the 
negative control. In our data, miRNA-99a down-regulates the active form of mTORC1 
and this down-regulation directly affects the phosphorylation of S6K1. Thus by 
decreasing the amount of active mTORC1, the phosphorylation and thus the active form 
of S6K1 is reduced. 
 The behavior of the HCT-116 line is opposite that of the HT-29 and CCD 841 cell 
lines. Thus, when miRNA-99a mimic is introduced into the cells, we observed an up-
regulation of the phosphorylation of S6K1as compared to the negative controls. There are 
at least two possible explanations for this: there are multiple pathways that ultimately 
converge on mTORC1, thus in this particular cell line, another pathway could be the 
predominate regulator of mTOR and override the effects of miRNA-99a on S6K1 
phosphorylation. In addition as seen in Figure 2, mTORC1 can directly phosphorylate 
S6K1, SGBP1 or 4EBP1. If mTOR predominantly phosphorylates IGBP1, this will then 
go on to dephosphorylate S6K1 via the PP2A catalytic pathway. One more possibility 
that could explain HCT-116’s different behavior, in comparison to the other two cell 
lines, is that HCT-116 is a mismatch repair deficient (Hereditary Non-polyposis 
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Colorectal Cancer [HNPCC]) cell line. This means that the mutation that leads to CRC in 
this cell line is different from that seen in sporadic CRC and normal tissue (our HT-29 
and CCD-841 cell lines). HNPCC is defective in DNA mismatch repair genes MSH2, 
MLH1, MSH6, PMS2, PMS1, TGFBR2 or MLH3, ultimately leading to microsatellite 
instability.
117-120, 122
 The fact that the pathology of this disease state is altered in 
comparison to sporadic CRC, could possibly lead to some of the different results 
observed with the HCT-116 cell line. The HCT-116 is a commonly utilized CRC cell-
line, and the fact that it is mismatch repair deficient is not widely appreciated. This is has 
great impact on much published literature.  
 We also wished to further investigate one other downstream protein of the mTOR 
pathway (4EBP1). We chose this protein since mTOR phosphorylation has the opposite 
effect on its function as compared to S6K1. The phosphorylation of 4EBP1 results in its 
deactivation. We would expect a similar phosphorylation trend to that seen with S6K1. 
This was, however, was not the case with all of the cell lines. With HT-29 and CCD-841 
cell lines we saw the opposite outcome of what we would have predicted. In the HCT-
116 cell line we observed what we would expect, i.e. when miRNA-99a mimic is 
introduced, phosphorylation of 4EBP1 is downregulated.  
 In conclusion, it is interesting that the HT-29 and normal epithelial cell line CCD-
841 behave opposite of the HCT-116 cell line. Thus when miRNA-99a is introduced, in 
HT-29 and CCD-841 we observe downregulation of the S6K1 phosphorylation and 
upregulation of 4EBP1 phosphorylation. With HCT-116, the exact opposite is observed 
with both proteins. A possible explanation for this could be the fact that HCT-116 is a 
mismatch repair deficient cancer in contrast to HT-29 and CCD-841 which are both 
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mismatch repair proficient. To test this, further work is being done, which is not covered 
in this thesis, which will investigate a Dukes D CRC cell line that is mismatch repair 




SPECIFIC AIM 3: TO DETERMINE IF TRANSFECTION OF HT-29, HCT-116 AND 




The motility of the cells lines was assessed to answer specific aim three. Since 
these cancer cell lines are classified by their metastatic potential, it is necessary to test the 
motility and invasion properties of each cell line. First, we needed to study the migration 
properties and once that was complete, we investigated the invasive nature of HT-29 and 
HCT-116. 
 Migration was tested first in HT-29 and HCT-116 utilizing the Boyden chamber 
method.  The Boyden chamber assay allows us to compare migration between transfected 
cell lines and negative controls.
124
 Once the transfection occurs, the transfected cell lines 
are then placed into the assay chambers and allowed to migrate into the bottom chamber. 
The technical specifications of these methods have been described previously in the 
Materials and Methods section (p. 70-72).  
 Transmigration assays allow us to observe the migration properties of specific 
cells in response to different chemoattractants.
124
 In our case, it allows us to investigate 
the migration properties of cells that have undergone transfection. One possible 
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disadvantage of using this type of assay is that cells under study will only migrate if 
motivated. In our study we chose to use the cells’ “food” FBS as a chemoattractant. By 
seeding the cells in an environment that is “starved,” in theory we give the cells an 
incentive to migrate to a place where nourishment is available. To encourage this 
movement, our cell lines are originally seeded in a 1% FBS solution while the chamber 
that the cells would migrate to had a FBS solution of 20%. Disadvantages of the 
procedure are that it is technically challenging, and there is limited cell visualization 
while the assay is being performed.  
1. MIGRATION DATA AND RESULTS 
 Initially we studied HT-29 to observe if transfection with miRNA-99a mimic 
would affect cell migration. Our sample size of five resulted in a reduced migration after 
miRNA-99a transfection equal to -0.045 ± 0.005, yet this was not statistically significant 
(p = 0.31) compared to the negative control (Figure 30). Once again the 5 samples had a 
similar trend but was not statistically significant. Turning our attention to the cell lines 
transfected with miRNA-99a antagomir, the migration assay was essentially the same as 




Figure 30. HT-29 Migration Assay after transfection with miRNA-99a Mimic (Blue) and 




Figure 30b. Numerical Density Values for HT-29 migration assay 
 
Normalized Migration (n=5) 
  99M 99A 
Average -0.045 -0.001 
Standard Deviation 0.005 0.014 







We observed a similar pattern in HCT-116, yet the observed relative density 
values were larger in magnitude. After transfection with miRNA-99a mimic a relative 
density value after cell migration was equal to an average of -0.325 ± 0.379 which did 
approach statistical significance, p = 0.064 (Figure 31).  
Similarly as with the HT29 (Dukes C cell line), HCT-116 antagomir assay studies 
were basically unchanged from their transfected negative control (Figure 31). This is not 
surprising as we did not have great success with the antagomir transfection being 
downregulated. Since the transfection was likely unsuccessful we did not expect there to 
be a significant influence on the pathway.  
 




Figure 31. HCT-116 Migration Assay after transfection with miRNA-99a Mimic (Blue) 
and Antagomir (Red). All data is normalized to the negative control. 
 
 




Normalized Migration (n=5) 
  99M 99A 
Average -0.325 -0.029 
Standard Deviation 0.379 0.613 
p-value (t-test) 0.064 0.460 
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B. MIGRATION ASSAY DISCUSSION 
 Although the migration assays did not yield statistical significant in any of the 
studies, they did show promising results for further inquiry. After transfection in both cell 
lines we would predict that a decreased migration would occur when compared to the 
negative control. This was observed in all samples but not statistically significant. HCT-
116 did approach statistical significance, which was promising for future studies.  
 The most likely reason we observed more migration in the Dukes D cell line 
compared to the Dukes C cell line is due to the fact that by definition the Dukes D cell 
line is a more aggressive cancer line. Another theory is that due to the fact that HCT-116 
is able to replenish the cells that are lost after transfection occurs because of its 
aggressive nature, as it has been shown that transfection itself can have a cytotoxic effect 







C. INVASION DATA AND RESULTS 
 
 The invasion assays once again utilize the Boyden chamber method and the 
specific details of experimental materials and method have been discussed previously.
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The difference between the migration and the invasion assays is the membrane coating 
that is applied to the Boyden chambers. The migration assay has a non-coated 
polycarbonate membrane inserts with 8 μm pores. The invasion assay uses these same 
polycarbonate membranes with the same pore size yet it is coated with a dried basement 
membrane matrix solution to recreate a functional basement membrane.  This is 
important because the ability of cells to invade through the basement membrane is 
essential to their metastatic potential.  
 Initially we evaluated the HT-29 cell line. We transfected HT-29 cells with 
miRNA-99a mimic and antagomir and then observed the amount of invasion at 48 hours. 
Cells transfected with miRNA-99a mimic exhibited minimal invasion. Our sample size of 
6 resulted in an average relative density equal to -0.034 ± 0.030, which was not 
significant as p = 0.36 (Figure 32). As expected from the migration studies, the 
transfected cells with miRNA-99a antagomir did not invade much and had an extremely 




Figure 32. HT-29 Invasion Assay after transfection with miRNA-99a Mimic (Blue) and 
Antagomir (Red). All data is normalized to the negative control. 
 
 




Normalized Invasion (n=5) 
  99M 99A 
Average -0.034 -0.023 
Standard Deviation 0.030 0.112 
p-value (t-test) 0.359 0.349 
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Next, we evaluated the invasive properties of HCT-116. The transfection of 
miRNA-99a mimic resulted in a relative density measurement of -0.041 ± 0.096(p = 0.20, 
Figure 33). The transfection of the antagomir had a density measurement of -0.005 ± 
0.111 (p = 0.46, Figure 33), as compared to the negative controls, i.e. there was basically 
no invasion with antagomir transfected cell lines as compared to the transfected negative 
control.  
 Overall data from the invasion assays were not as clear cut as those from the 
migration assays. Some possible explanations for this:  
 Prior studies of the HT-29 cell line showed that it had minimal migration and 




 The motility of the antagomir transfected cell lines could be due to the lack of 
successful antagomir transfection.   
 The effects of transfection itself can be cytotoxic after certain time periods.128 
Although Lipofectamine 3000
®
 has not been tested for this to our knowledge, its 
predecessor Lipofectamine 2000
®




Figure 33.  HCT-116 Invasion Assay after transfection with miRNA-99a Mimic (Blue) 
and Antagomir (Red). All data is normalized to the negative control. 
 




Normalized Invasion (n=5) 
  99M 99A 
Average -0.041 -0.005 
Standard Deviation 0.096 0.111 




  The migration data are interesting in that HT-29 and HCT-116 had similar 
patterns of migration and invasion after transfection with miRNA-99a mimic. The more 
promising data with HCT-116 are not surprising as it has been previously reported that 
HT-29 cell lines have limited motility in migration assays.
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 The invasion data showed a similar trend as the migration data. Both cell lines 
exhibited reduced invasion after miRNA-99a transfection although this was not 
statistically significant. Invasion was not observed with either CRC cell line following 
antagomirs transfection. This could be due to the difficulty in antagomir transfection that 




FINAL DISCUSSION AND OVERVIEW 
 Colorectal Cancer (CRC) is the third most common cancer in men and women in 
the United States.
1
 According to the Centers for Disease Control and Prevention’s most 
recent statistics in 2011 approximately 135,260 people were diagnosed with CRC in that 
year alone.
1
 51,783 reported deaths were credited to CRC, including 26,804 men and 
24,979 women.
1
 Out of all states, Kentucky ranked number one in incidence for male 
cases of CRC with 58.8 per 100,000 individuals. Females in the state of Kentucky ranked 
#3 out of all states with a rate of 40.6 per 100,000 individuals and combined Kentucky 
ranked #1 out of all states at a rate of 48.9 per 100,000 individuals.
1
 All of these being 
well above the national average for new cases of CRC in individual states. 
 Although these might be daunting statistics, this poses a challenge  from the 
researchers stand point, as it opens up an opportunity to focus on an area that potentially 
could  change thousands of lives. CRC if caught early is potentially curable.   
 One pathway that has currently gained a large amount of attention because of its 
implication in cancer metastasis is the mechanistic target of rapamycin the mTOR 
pathway. The mTOR pathway is an extensive and complex pathway that has a great deal 
of control over the translation of many eukaryotic proteins.  
 Prior work shows that multiple upstream regulators control mTORC1, these are 
not limited to but include PI3K/Akt route to mTORC1.
130
 It has been shown that the 





mTORC2 directly interacts with the AKT pathway which is one of the many upstream 
regulators of mTORC1.  
 Our work investigated the mTOR pathway and miRNA-99a’s influence on CRC 
cell lines within this pathway. With better understanding of this pathway and the 
influence miRNA-99a on this pathway, many avenues of study for potential therapeutic 
intervention for metastatic CRC may become available.  
A. SUMMARY OF FINDINGS 
We initially needed to confirm successful cell line transfection of CCD-841 
(normal colon epithelial cell line), HT-29 (Dukes C) and HCT-116 (Dukes D) cell lines. 
miRNA-99a mimic was successfully transfected in all three cell lines. This was shown 
with representative qRT-PCR transfection results of miRNA -99a indicating upregulation 
of expressed miRNA-99a after transfection with miRNA-99a mimic (Figure 9-11). 
 miRNA 99a antagomir transfection  was not as successful (Figure 9-11). Three 
cell lines did show a miRNA-99a level close to baseline, however, not all cell lines were 
downregulated. Moving forward, we therefore focused our efforts on mimic transfection, 
especially when investigating the proteins in the mTOR pathway. We did pursue motility 
assays using both mimics and the antagomirs, although we did not expect much success 
for the antagomir motility studies due to our limited results with antagomir transfection.  
 To answer Specific Aim 2, we utilized Western blot analysis of mTOR protein, 
S6K1 and 4EBP1. Most data was in agreement to what one would predict after 
transfection with a miRNA-99a mimic. Our data showed HT-29 phosphorylated average 
relative density of 0.06 ± 0.02 compared to the negative control 0.15 ± 0.05, although not 
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statistically significant (p = 0.07) it did have the same trend in all samples. This is what 




A similar pattern of mTOR was seen after transfection in HCT-116 and CCD-841. 
In HCT-116 an average relative density of phosphorylated antibodies was 0.03 ± 0.00. 
This was compared to the negative controls average of 0.05 ± 0.04. Which was a 
statistically significant difference (p = 0.04). The total antibody resulted an average 
density of 0.13 ± 0.13 compared to the negative control of 0.25 ± 0.23, which was not a 
significant difference (p = 0.23). Finally, the CCD-841 cell lines, resulted in 
phosphorylated density average of 0.04 ± 0.01 compared to the negative control which 
was equal to 0.06 ± 0.01. This was not statistically significant, p = 0.19. Probing for the 
total antibody resulted in an average of 0.02 ± 0.01 compared to the negative control 
which was equal to 0.08 ± 0.05 (p = 0.14).    
S6K1 phosphorylated only Western blot analysis resulted in a relative density 
measurement of 0.19 ± 0.04. This was compared to the transfected negative control 
which resulted in a relative density of 0.22 ± 0.07, which was not statistically significant 
(p = 0.15) but all samples had the same trend.  mTOR total probe resulted in a significant 
difference (p = 0.02) between miRNA-99a mimic and its transfected negative control. 
The average density after transfection was 0.09 ± 0.07 compared to the negative control, 
0.10 ± 0.07.  
Then 4EBP1 was elucidated under Western blot analysis. HT-29 cell line shows 
the results of phosphorylated only 4EBP1, which is 0.46 ± 0.11 for miRNA-99a mimic 
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compared to the negative control, 0.42 ± 0.09. This difference was not statistically 
significant with p = 0.28. Next, total expression of 4EBP1 shows a similar upregulation 
compared to negative control trend, with the relative density average being 1.17 ± 0.87 
compared to the negative control average of 0.87 ± 0.60, which was not significantly 
different.  
Our attention next shifted to HCT-116, the Dukes’ D cell line. Western blot 
analysis showed a relative density of 0.21 ± 0.11 compared to the negative control 0.24 ± 
0.04. Similarly, the total protein was downregulated (1.61 ± 0.27) compared to the 
negative control (1.78 ± 0.36). Neither were statistically significant with p values equal to 
0.31, 0.25 respectively.  
Finally CCD-841 phosphorylated only versus negative control Western blots 
basically showed no difference, 0.16 ± 0.09 compared to 0.16 ± 0.11 respectively. 4EBP1 
total expression showed upregulation after transfection with miRNA-99a compared to 
negative control.  A relative density of 0.14 ± 0.12 was compared to the negative control 
equal to 0.18 ± 0.14. Once again the p value was not statistically significant but it was 
approaching significance (p = 0.06) 
Out of all the Western Blots only three showed statistical significance compared 
to the negative control. When HCT-116 was evaluated for phosphorylated only mTOR. 
Next when HT-29 was evaluated for total S6K1. Finally, when CCD841 was evaluated 
for phosphorylated only S6K1.  
The migration data for HT-29 and HCT-116 were similar to what was predicted. 
With the introduction of miRNA-99a mimic a decrease in motility was observed in both 
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cell lines. Although this was the appropriate trend, neither of these data sets was 
statistically significant. The antagomir transfection assays did not show much difference 
compared to the non-transfected cells.   
The invasion data showed a similar trend after miRNA-99a mimic transfection. 
HT-29 and HCT-116 both exhibit decreased invasion following miRNA-99a transfection, 
but once again neither were statistically significant compared to negative control but all 
samples had a similar trend. Similar to the migration data the antagomir studies showed 
no difference.  This was predicted due to the unsuccessful transfection of the antagomirs 
that was observed.  
Overall, our data are promising for future studies. They highlight the role of 
miRNA-99a and its effect in the up and down-regulation of colorectal cancer cell lines. 
This is promising as it could open up avenues of possible therapeutic intervention. This 
thesis was limited only to cell lines of have a high degree of metastatic potential. Future 
studies would need to be done to delineate the impact of miRNA-99a on cancer cell lines 
of lesser metastatic potential. In addition future studies need to be undertaken to examine 
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99M  miRNA-99a mimic 
99A  miRNA-99a antagomir 
M-  miRNA-99a mimic negative control 
A-  miRNA-99a antagomir negative control 
AUC  Area Under the Curve 
BC  Breast Cancer 
BCA  Bicinchoninic acid 
CA 19-9 Carbohydrate antigen 19-9 
CAA  Colorectal Advanced Adenomas 
CCSP  Colon-cancer-secreted-protein 
CEA  Carcinoembryonic antigen 
CRC  Colorectal Cancer 
CSA  Colon cancer specific antigen 
CT  Cycle threshold  
DMSO  Dimethyl sulfoxide 
eIF4EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 
EtOH  Ethanol  
FBS  Fetal bovine serum 
HKG  Housekeeping gene 
LC  Lung Cancer 
miRNA micro-Ribonucleic acid 
mTOR  Mechanistic target of rapamycin  
mTORC1 mTOR Complex 1 
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PBS  Phosphate buffered saline 
PC  Pancreatic Cancer 
PVDF  Polyvinylidene difluoride  
qRT-PCR Real time polymerase chain reaction 
RCF  Relative centrifugal force  
RISC  RNA-induced silencing complex 
ROC  Receiver operating characteristic 
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